CHIR-99021 (CT99021) HCl

Name: CHIR-99021 (CT99021) HCl
Brand: Selleck Chemicals
SKU: S2924
Rating: 5 (173 reviews)

For research use only.

Catalog No.S2924

173 publications

CHIR-99021 (CT99021) HCl Chemical Structure

Molecular Weight(MW): 501.8

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.

Selleck's CHIR-99021 (CT99021) HCl has been cited by 173 publications

Cell, 2020, 30;181(3):621-636

PubMed: 32259487 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cell Stem Cell, 2019, 24(5):802-811

PubMed: 30880024 ( click the link to review the publication )

Cell, 2018, 174(2):406-421

PubMed: 29887375 ( click the link to review the publication )

Cell, 2018, 174(2):391-405

PubMed: 29937225 ( click the link to review the publication )

Cell Stem Cell, 2018, 22(3):369-383

PubMed: 29499153 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):462-477

PubMed: 28111200 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(5):720-731

PubMed: 28343982 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(4):518-532

PubMed: 28017796 ( click the link to review the publication )

Nature, 2016, 17;539(7629):452-455.

PubMed: 27783602 ( click the link to review the publication )

Nature, 2015, 13;524(7564):234-8.

PubMed: 26176921 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14413

PubMed: 25945737 ( click the link to review the publication )

Cell Stem Cell, 2015, 10.1016/j.stem.2015.04.020

PubMed: ( click the link to review the publication )

Nat Biotechnol, 2014, 32(11):1121-33

PubMed: 25211370 ( click the link to review the publication )

Nature, 2013, 8;500(7461):222-6.

PubMed: 23812591 ( click the link to review the publication )

Cell, 2013, 26;155(1):135-47.

PubMed: 24074866 ( click the link to review the publication )

Cell Res, 2020, 30(1):21-33

PubMed: 31729468 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2585

PubMed: 32444791 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa067

PubMed: 32016422 ( click the link to review the publication )

EMBO J, 2020, 15;39(8):e102961

PubMed: 32090361 ( click the link to review the publication )

Dev Cell, 2020, 6;53(1):42-59

PubMed: 32109383 ( click the link to review the publication )

Biomaterials, 2020, 248:120013

PubMed: 32278152 ( click the link to review the publication )

Biomaterials, 2020, 249:120015

PubMed: 32311594 ( click the link to review the publication )

Cell Rep, 2020, 17;30(11):3917-3931

PubMed: 32187559 ( click the link to review the publication )
Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Death Differ, 2020, 1

PubMed: 32483381 ( click the link to review the publication )

Protein Cell, 2020, 10.1007/s13238-020-00713-x

PubMed: 32277346 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cardiovasc Res, 2020, 29 pii: cvaa017

PubMed: 31995179 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 15;39(1):64

PubMed: 32293507 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2020, 6;19:1299-1308

PubMed: 32160702 ( click the link to review the publication )

Cells, 2020, 5;9(6):E1406

PubMed: 32516938 ( click the link to review the publication )

J Mol Cell Biol, 2020, 30 pii: mjaa010

PubMed: 32232340 ( click the link to review the publication )

ACS Infect Dis, 2020, 21

PubMed: 32329611 ( click the link to review the publication )

Sci Total Environ, 2020, 6;725:138433

PubMed: 32302844 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

FEBS J, 2020, 287(1):122-144

PubMed: 31569299 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44727

PubMed: 32471864 ( click the link to review the publication )

Environ Pollut, 2020, 261:114153

PubMed: 32088431 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15433

PubMed: 32468734 ( click the link to review the publication )

Int J Mol Sci, 2020, 22;21(8)

PubMed: 32331350 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):209

PubMed: 31937807 ( click the link to review the publication )

J Biol Chem, 2020, 15

PubMed: 32295843 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

J Pharmacol Exp Ther, 2020, 373(3):429-437

PubMed: 32217769 ( click the link to review the publication )

J Biomed Mater Res A, 2020, 108(3):496-514

PubMed: 31707752 ( click the link to review the publication )

Sci China Life Sci, 2020, 63(1):1-17

PubMed: 31564034 ( click the link to review the publication )
Brain Sci, 2020, 3;10(6):E344

PubMed: 32503260 ( click the link to review the publication )

PLoS One, 2020, 3;15(4):e0230966

PubMed: 32243463 ( click the link to review the publication )

EBioMedicine, 2020, 53:102695

PubMed: 32143182 ( click the link to review the publication )

Cytometry A, 2020, 97(4):363-377

PubMed: 31774248 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 1;S2352-345X(20)30088-6

PubMed: 32497793 ( click the link to review the publication )

Cell Host Microbe, 2020, 27(1):41-53

PubMed: 31862381 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):100

PubMed: 32127035 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(9):1152-1163

PubMed: 31481791 ( click the link to review the publication )

Blood, 2019, blood.2019001037

PubMed: 31570489 ( click the link to review the publication )

Nat Commun, 2019, 10(1):928

PubMed: 30804331 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2939

PubMed: 31270324 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3477

PubMed: 31375664 ( click the link to review the publication )

Sci Adv, 2019, 5(11):eaax7525

PubMed: 31807705 ( click the link to review the publication )

Dev Cell, 2019, 50(2):212-228.e6

PubMed: 31178404 ( click the link to review the publication )

Cell Syst, 2019, 8(5):427-445

PubMed: 31078527 ( click the link to review the publication )

Cell Rep, 2019, 26(13):3643-3656

PubMed: 30917318 ( click the link to review the publication )

Cell Rep, 2019, 29(8):2461-2472

PubMed: 31747613 ( click the link to review the publication )

Int J Cancer, 2019, 144(2):389-401

PubMed: 29978469 ( click the link to review the publication )

Oncogene, 2019, 38(15):2788-2799

PubMed: 30542117 ( click the link to review the publication )

Stem Cell Reports, 2019, 13(3):485-498

PubMed: 31402336 ( click the link to review the publication )

Mol Metab, 2019, 24:80-97

PubMed: 30930126 ( click the link to review the publication )

PLoS Pathog, 2019, 15(3):e1007667

PubMed: 30901352 ( click the link to review the publication )

FASEB J, 2019, 33(2):2694-2706

PubMed: 30307767 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0605

PubMed: 31395667 ( click the link to review the publication )
Front Neurosci, 2019, 13:867

PubMed: 31551670 ( click the link to review the publication )

Front Physiol, 2019, 10:818

PubMed: 31316396 ( click the link to review the publication )

Cell Cycle, 2019, 18(19):2495-2508

PubMed: 31411525 ( click the link to review the publication )

Mol Med Rep, 2019, 19(6):5440-5452

PubMed: 31059099 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Gastroenterology, 2018, 155(5):1508-1523.e10

PubMed: 30055169 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5230

PubMed: 30531796 ( click the link to review the publication )

Sci Adv, 2018, 4(5):eaat0351

PubMed: 29795786 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(47):E11071-E11080

PubMed: 30381455 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Cell Rep, 2018, 25(7):1966-1981.e4

PubMed: 30428361 ( click the link to review the publication )

Cell Rep, 2018, 25(9):2563-2576

PubMed: 30485820 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Stem Cell Reports, 2018, 11(2):497-513

PubMed: 30033084 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):22

PubMed: 29426364 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):598

PubMed: 29789524 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(9):1095-1106

PubMed: 30251630 ( click the link to review the publication )

Dig Dis Sci, 2018, 63(10):2604-2616

PubMed: 29948558 ( click the link to review the publication )

Biol Open, 2018, 7(9)

PubMed: 30135081 ( click the link to review the publication )

Methods Mol Biol, 2018, 1649:473-488

PubMed: 29130217 ( click the link to review the publication )

Curr Protoc Hum Genet, 2018, 10.1002/cphg.64

PubMed: 29979824 ( click the link to review the publication )

Methods Mol Biol, 2018, 1733:127-136

PubMed: 29435928 ( click the link to review the publication )

Cell Res, 2017, 27(6):815-829

PubMed: 28429771 ( click the link to review the publication )
Mol Cell, 2017, 66(4):568-576

PubMed: 28483418 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(31):25929-25940

PubMed: 28718622 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3107

PubMed: 29022923 ( click the link to review the publication )

Biomater Sci, 2017, 5(8):1567-1578

PubMed: 28715029 ( click the link to review the publication )

Stem Cell Res Ther, 2017, 8(1):156

PubMed: 28676082 ( click the link to review the publication )

Sci Rep, 2017, 7(1):9490

PubMed: 28842634 ( click the link to review the publication )

Biofabrication, 2017, 9(2):025007

PubMed: 28287080 ( click the link to review the publication )

JCI Insight, 2017, 2(18)

PubMed: 28931764 ( click the link to review the publication )

Stem Cells, 2016, 34(7):1765-75

PubMed: 26946228 ( click the link to review the publication )

Sci Rep, 2016, 6:23817

PubMed: 27026509 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0161508

PubMed: 27560518 ( click the link to review the publication )

Exp Ther Med, 2016, 12(6):3851-3858

PubMed: 28101169 ( click the link to review the publication )

Methods Mol Biol, 2016, 1353:181-90

PubMed: 25523811 ( click the link to review the publication )

Methods Mol Biol, 2016, 1480:153-65

PubMed: 27659983 ( click the link to review the publication )

Stem Cell Reports, 2016, 7(5):884-896

PubMed: 27720906 ( click the link to review the publication )

Nat Commun, 2015, 6:7413

PubMed: 26172574 ( click the link to review the publication )

Dev Cell, 2015, 32(6):667-77

PubMed: 25805134 ( click the link to review the publication )

Stem Cell Res, 2015, 10.1016/j.scr.2015.05.004

PubMed: ( click the link to review the publication )

Stem Cells, 2015, 33(3):686-98

PubMed: ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Mol Neurobiol, 2015, 10.1007/s12035-014-9084-z

PubMed: 25663198 ( click the link to review the publication )

J Thromb Haemost, 2015, 10.1111/jth.12954

PubMed: 25858425 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

Stem Cells Dev, 2015, 10.1089/scd.2014.0422

PubMed: 25751301 ( click the link to review the publication )
Cell Transplant, 2015, 10.3727/096368914X685762

PubMed: 25562386 ( click the link to review the publication )

Biol Open, 2015, 4(1):48-61

PubMed: ( click the link to review the publication )

J Physiol, 2015, 593(5):1147-57

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144572

PubMed: 26695765 ( click the link to review the publication )

Sci Rep, 2015, 5:9718

PubMed: 25864432 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(6):1128-1142

PubMed: 26626177 ( click the link to review the publication )

Methods Mol Biol, 2015, 10.1007/7651_2015_220

PubMed: 25762297 ( click the link to review the publication )

Methods Mol Biol, 2015, 1264:453-63

PubMed: 25631034 ( click the link to review the publication )

Cell Biology International Reports, 2015, 10.1002/cbi3.10019

PubMed: ( click the link to review the publication )

Circ Res, 2014, 115(6):556-66

PubMed: 25015077 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(12):4484-9

PubMed: 24623855 ( click the link to review the publication )

Biomaterials, 2014, 35(5):1367-77

PubMed: 24268663 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(4):594-605

PubMed: 25358788 ( click the link to review the publication )

Stem Cell Rep, 2014, 3(5):804-16

PubMed: 25418725 ( click the link to review the publication )

Acta Biomater, 2014, 10(2):604-12

PubMed: 24200714 ( click the link to review the publication )

Protein Cell, 2014, 5(1):59-68

PubMed: 24474197 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):812-22

PubMed: 24552772 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(4):990-1007

PubMed: 24482122 ( click the link to review the publication )

J Biol Chem, 2014, 289(47):32628-38

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 10.1074/jbc.M114.580076

PubMed: 25301940 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14341-50

PubMed: 24692544 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):724-735

PubMed: ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Stem Cells Dev, 2014, 23(14):1688-703

PubMed: 24641164 ( click the link to review the publication )
Stem Cells Dev, 2014, 10.1089/scd.2014.0011

PubMed: 24805295 ( click the link to review the publication )

Exp Cell Res, 2014, 328(2):351-60

PubMed: 25172557 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115854

PubMed: 25541965 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85089

PubMed: 24465482 ( click the link to review the publication )

PLoS One, 2014, 9(4):e92304

PubMed: 24743237 ( click the link to review the publication )

Exp Biol Med, 2014, 239(10):1390-402

PubMed: 24951472 ( click the link to review the publication )

Theriogenology, 2014, 82(2):283-93

PubMed: 24853281 ( click the link to review the publication )

Cell Reprogram, 2014, 10.1089/cell.2014.0028

PubMed: 25084370 ( click the link to review the publication )

J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2):151-6

PubMed: 24710923 ( click the link to review the publication )

University of GOTHENBURG, 2014, 5495

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:6425

PubMed: 25236849 ( click the link to review the publication )

Methods Mol Biol, 2014, 10.1007/7651_2014_172

PubMed: 25520292 ( click the link to review the publication )

Nat Commun, 2013, 4:2628

PubMed: 24165455 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(52):E5039-48

PubMed: 24248365 ( click the link to review the publication )

Stem Cell Res, 2013, 12(2):364-375

PubMed: 24365601 ( click the link to review the publication )

Stem Cell Rep, 2013, 1(4):360-10

PubMed: 24319670 ( click the link to review the publication )

Antioxid Redox Sign, 2013, 20(18):2907-22

PubMed: 24219064 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):454-67

PubMed: 24282277 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(8):4102-16

PubMed: 23628704 ( click the link to review the publication )

J Biol Chem, 2013, 288(49):35500-10

PubMed: 24165128 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1329-40

PubMed: 23867056 ( click the link to review the publication )

Nat Protoc, 2012, 8(1):162-75

PubMed: 23257984 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(27):E1848-57

PubMed: 22645348 ( click the link to review the publication )

Stem Cells, 2012, 30(9):1863-74

PubMed: 22761013 ( click the link to review the publication )
Carcinogenesis, 2012, 33(3):529-37

PubMed: 22201186 ( click the link to review the publication )

J Biol Chem, 2012, 287(2):893-904

PubMed: 22102280 ( click the link to review the publication )

PLoS One, 2012, 7(10):e47312

PubMed: 23077590 ( click the link to review the publication )

BMC Dev Biol, 2012, 12:21

PubMed: 22846383 ( click the link to review the publication )

Bachelor of Science, 2012, East China Normal University

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Biological Activity

Description

Targets

GSK-3β ^[1] (Cell-free assay)	GSK-3α ^[1] (Cell-free assay)
6.7 nM	10 nM

In vitro

CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, CHIR-99021 shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. CHIR-99021 induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM. ^[1] In addition to simulating the actions of insulin, inhibition of GSK-3 by CHIR-99021 (3 μM) increases free cytosolic β-catenin by 1.9-fold, mimicking the canonical Wnt signaling pathway in 3T3-L1 preadipocytes. During any of the first 3 days of differentiation, CHIR-99021 treatment inhibits the preadipocyte differentiation with IC50 of 0.3 μM by blocking induction of CCAAT/enhancer-binding protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ). ^[2] Unlike lithium chloride and AR-A014418, CHIR-99021 treatment does not reduce the viability of INS-1E cells even at high concentrations. Instead, CHIR-99021 robustly increases the rate of proliferation of INS-1E cells in a dose-dependent manner, and significantly inhibits INS-E cell death induced by high glucose and high palmitate in a concentration-dependent manner. CHIR-99021 promotes primary beta cell replication in isolated rat islets at concentrations as low as 1 μM, with 2-3 fold increase of cell replication at 5 μM of CHIR-99021 treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
3T3-L1	NHvENW5HfW6ldHnvckBCe3OjeR?=	NFf2O4o{KM7:TR?=	Mmi2OEBp	NGPaPYpFVVOR	M2TLWWlvcGmkaYTzJJBz\WGmaYDvZ5l1\SCmaX\m[ZJmdnSrYYTpc44>	NITxTJUyOjB3NUKwNC=>
insulin receptor–expressing CHO-IR	NYPmSGI1TnWwY4Tpc44hSXO\|YYm=	MmLzOVAxKG6P	NVSwfXZ7OzBibXnu	NWLnRmkxTE2VTx?=	NFLGdGFC[3SrdnH0[ZMhT2y7Y3;n[Y4hW3mwdHjhd4UhMEeVKR?=	NV[5VXNIOTJ4ME[0PVc>
H4IIE	MVLGeY5kfGmxbjDBd5NigQ>?	NGLMWnIyOCEQvF2=	NUDpToJsOjRiaB?=	MkjISG1UVw>?	M3vRcnJm\3WuYYTld{DPui2lYYTlcolvKGGldHn2bZR6KGGwZDDUTXJGKGOxboThbY5qdmdicILvcY91\XJiYXP0bZZqfHl?	MWOxOVM2ODF7NR?=
Oct4/Sox2/Klf4-infected MEFs	NUjvfYJ7TnWwY4Tpc44hSXO\|YYm=	NXW4SJpIOTBizszN	M2PvUlI5KGR?	MU\EUXNQ	MXXQdo9ud3SnczDNSWZ{KHKncILv[5JidW2rbnegWJJidnOmdXPl[EBjgSCRY4S0MEBUd3h{LDDhcoQhU2yoNB?=	NXrFVlVoOTl6M{mwOVU>
Sca-1+ HPC	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoP4NkDPxE1?	Mm\DOkBl	NEfaT4hFVVOR	NIfMUlFUgW6ncnfpd5Rq[2GubImgdJJwdW:2ZYOgV4NiNTFtwrDIVGMheHKxbHnm[ZJifGmxbjDhcoQh[2:ub375JIZwem2jdHnvckB1d2endHjldkB4cXSqIFXHSi=>	M{nJe\|IyPjJ2M{S4
HMC1.2	NGrRRXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPuTGc{OCEQvF2=	M{fkXlczKGh?	NVjPPFJ1TE2VTx?=	NWr6VVhlWmWmdXPld{Bk\WyuIIP1dpZqfmGu	MXuyNlA{QTNyMR?=
Endothelial cell(EC)	NFPEV\|RHfW6ldHnvckBCe3OjeR?=	NH\3VpI{KM7:TR?=		M{j0SmROW09?	M{nEOXBzd22xdHXzJIVv\G:2aHXsbYFtKGOnbHygLGVEMSCmaX\m[ZJmdnSrYYTpc44>	MmTMNlIxPTJyME[=
PANC1	NY\xcohZSXCxcITvd4l{KEG\|c3H5	MoXPxsA2KM7:TR?=	M1nmblczKGh?	NXvHSoVZTE2VTx?=	M322PXRzcWepZYLzJIFvKGGyb4D0c5Rq[yC{ZYPwc45{\Q>?	NWSzRpFJOjJ{MEGxPFY>
INS-1E	MXzGeY5kfGmxbjDBd5NigQ>?	MnHiNk42KM7:TR?=	M2TNZlI1KGh?	NX3L[odPTE2VTx?=	M3zh[2lv\HWlZYOgZUBz\WS3Y4Tpc44hd2ZiTmCxJI93\XKneIDy[ZN{cW:w	NEnDdXMzOjR{N{ewOC=>
hiPSC-NPs	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HzVFPjiIoQvF2=	Mn7jO\|IhcA>?	NWrzWGxETE2VTx?=	MUjJcoNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;uxsA>	MYWyNlY1OjZ6Nx?=
platelets	M2XjT2Z2dmO2aX;uJGF{e2G7	M1naTFExKM7:TR?=	MXexOUBucW5?	M4L4RWROW09?	NX;KVodKUW6lcnXhd4V{KHSqcn;tZolvNW2nZHnheIVlKHCuYYTlcIV1KGGpZ4Ll[4F1cW:wIHHu[EBCXFBic3XjdoV1cW:w	NGfU[5MzOzJ\|OUi3Oy=>
DN3	NH:3NIVHfW6ldHnvckBCe3OjeR?=	M1fGVlExKM7:TR?=	NXW3W2dEQTZiaB?=	M4HZPGROW09?	MUDJcoNz\WG\|ZYOgZ4VtdCCmZY\lcI9xdWWwdDDhcoQheHKxbHnm[ZJifGmxbh?=	NULSV4RDOjN3Mk[5PFk>
embryonic stem cells (ESC)	MlLHSpVv[3Srb36gRZN{[Xl?	NX7lWHdoOyEEtV2=	NUnGcZh2OTFiZB?=	NITwWGNFVVOR	NVL4doVmWHKxbX;0[ZMhe2WuZj3y[Y5mf2GuIH;mJI5iy6:4ZT30fZBmKG2xdYPlJIVu[nK7b37pZ{B{fGWvIHPlcIx{KCiHU1Op	NXG1cXV7OjN6NEOzNVI>
H460	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfMOUDDvU1?	M{PRVVI1KGh?	NXzaTmg5TE2VTx?=	MUfQdo9ud3SnczDj[YxtKHC{b3zp[oVz[XSrb36=	MYiyOFM3PzZ6OB?=
H157	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v3[lUhyrWP	MlKyNlQhcA>?	NGqxT25FVVOR	M{HkV3Bzd22xdHXzJINmdGxicILvcIln\XKjdHnvci=>	NWjRXJVoOjR\|Nke2PFg>
H460	MlfJRZBweHSxc3nzJGF{e2G7	NWG4eVdzPSEEtV2=	M{TZWlI1KGh?	NXT2c2NDTE2VTx?=	MnPNRZR1\W63YYTld{Bk\WyuIHHwc5B1d3Orcx?=	NYq2dVl7OjR\|Nke2PFg>
H157	Mof1RZBweHSxc3nzJGF{e2G7	NF;zfHc2KML3TR?=	MWqyOEBp	NFjiSVJFVVOR	MX7Ec4V{KG6xdDDzbYdvcW[rY3HueIx6KGGoZnXjeEBieG:ydH;zbZM>	NYD1OWlwOjR\|Nke2PFg>
A549	MXnBdI9xfG:\|aYOgRZN{[Xl?	M2rwOlUhyrWP	MmLFNlQhcA>?	NUDvVWhDTE2VTx?=	MUHJcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXN?	MnXWNlQ{Pjd4OEi=
Neural progenitor cells	NVLoN5J2TnWwY4Tpc44hSXO\|YYm=	NWG4WJlGOyEQvF2=	MojyNVAh\A>?	NV3pcmNjTE2VTx?=	MnHoTY5lfWOnczDn[Y5memG2aX;uJI9nKG6ndYLhcEBxem:pZX7peI9zKGOnbHzz	NEi2fW4zPDZ\|OECzOC=>
ES-D3	MWjDfZRwfG:6aXOgRZN{[Xl?	NFHJNocyOMLizszN	NH7BS2k{KGR?	NEPaSpNFVVOR	MXXJcoR2[2W\|IH3v[IVz[XSnIHP5eI91d3irY3n0fUB4cXSqIFnDOVAhd2ZiND65JO69VQ>?	NVH0em9sOjR5N{mzOlU>
ES-CCE	NFnQUphEgXSxdH;4bYMhSXO\|YYm=	Ml\iNVDDqM7:TR?=	NYjFU4MyOyCm	NE\wWGpFVVOR	M1PW[Wlv\HWlZYOgcY9l\XKjdHWgZ5l1d3SxeHnjbZR6	NIrlZWwzPDd5OUO2OS=>
ES-D3	MnjzSpVv[3Srb36gRZN{[Xl?	MkX1OeKh\|ryP	NYXK[ZFZOyCm	M3m1UGROW09?	NUfMempmW3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	MmLrNlQ4Pzl\|NkW=
ES-CCE	MmS5SpVv[3Srb36gRZN{[Xl?	MlLpOeKh\|ryP	MmLpN{Bl	NEHTN5RFVVOR	NXLObpMyW3S{b37ncJkhcW6mdXPld{B1cGViYXP0bZZqfHlib3[gW451N2KndHGtZ4F1\W6rbjDwZZRpf2G7	M2HjPFI1Pzd7M{[1
SW982	NHXqXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TqZWlEPTB;MD6yNVQyPiEQvF2=	MmjqV2FPT0WU
GCT	M3XUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTBwM{C2O\|Ih\|ryP	MULTRW5ITVJ?
769-P	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDCdnpKSzVyPUCuOVg1QTlizszN	Mn\PV2FPT0WU
LOXIMVI	NUjQS\|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwNUi4N\|Ih\|ryP	NVPzRYVKW0GQR1XS
D-336MG	M13EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDnTWM2OD1yLki0OlIh\|ryP	Mnq5V2FPT0WU
S-117	M3TNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTUNWFKSzVyPUCuPVIyOzFizszN	M1;LVnNCVkeHUh?=
D-247MG	NIDIV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrOOGhKSzVyPUCuPVQ5PTJizszN	MWTTRW5ITVJ?
TYK-nu	NGTpSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIqySZVKSzVyPUGuNFc6OTJizszN	MXzTRW5ITVJ?
A498	NYLzTnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jEW2lEPTB;MT6zNFQ3QSEQvF2=	MoLUV2FPT0WU
BCPAP	NGTWNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK1cIxKSzVyPUGuOlY5QThizszN	NFe1[ZhUSU6JRWK=
KYSE-180	NVjNT\|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K4[WlEPTB;MT63Nlc5QCEQvF2=	NIfIZnJUSU6JRWK=
MIA-PaCa-2	NGHPUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzLNJp4UUN3ME2xMlc2QTd5IN88US=>	Mmi0V2FPT0WU
HCC1395	NGDxUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLGTWM2OD1zLke4Nlc{KM7:TR?=	MYfTRW5ITVJ?
RS4-11	NYrLVIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrLW3lnUUN3ME2xMlk2PDF3IN88US=>	NF74OIhUSU6JRWK=
NCI-H2122	NYW3foI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvOfHBlUUN3ME2yMlI4Pjh2IN88US=>	M33TNHNCVkeHUh?=
SNU-423	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJwNEm3PFch\|ryP	NWi5cmZDW0GQR1XS
SK-LMS-1	NHz3PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETmUoZKSzVyPUKuOlQyOjhizszN	MUDTRW5ITVJ?
RPMI-7951	MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3wNVNKSzVyPUKuO\|AyQTNizszN	MUHTRW5ITVJ?
COLO-829	NUfQSo9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLBZmhIUUN3ME2yMlc3PTRizszN	MoG4V2FPT0WU
SCC-9	NXfaOI91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTJwOUW0PFUh\|ryP	MXnTRW5ITVJ?
A704	NFPKb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTNwMEixNkDPxE1?	NH3nUZNUSU6JRWK=
HOP-62	NGW1b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnHZml[UUN3ME2zMlM3ODV2IN88US=>	MYnTRW5ITVJ?
HCC1569	M4r1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XoOWlEPTB;Mz60PFMxPSEQvF2=	NH35TGJUSU6JRWK=
A172	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTNwN{W0PVgh\|ryP	MWPTRW5ITVJ?
MOLT-16	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPGNVVKSzVyPUOuPFg2PTZizszN	NG[2clFUSU6JRWK=
TE-15	MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\2fHZpUUN3ME2zMlk2OzR\|IN88US=>	MX7TRW5ITVJ?
OE19	NVruZ2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTNwOU[0OVEh\|ryP	NVTpVJVXW0GQR1XS
MHH-ES-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLwTWM2OD12LkC0OVQ2KM7:TR?=	MmfkV2FPT0WU
NKM-1	M124Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfuSYdKSzVyPUSuNVM6PzFizszN	MUjTRW5ITVJ?
RCC10RGB	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTRwMkm0O\|kh\|ryP	NX3TSmVzW0GQR1XS
BxPC-3	NYPuUIRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDHSnZKSzVyPUSuO\|A{QTFizszN	NHnYcHhUSU6JRWK=
ALL-PO	NHvmW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX:4WlR1UUN3ME20Mlg{QDV6IN88US=>	NIL2WndUSU6JRWK=
SK-OV-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTRwOUmzOEDPxE1?	Mn:2V2FPT0WU
SW1710	NGCxWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTVwNEK0OVYh\|ryP	MmT6V2FPT0WU
NCI-H2452	NHHRWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HZTGlEPTB;NT60OVYzQCEQvF2=	MmjHV2FPT0WU
D-392MG	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\uR2lEPTB;NT60PVE1PSEQvF2=	NVnJOGxVW0GQR1XS
LB2518-MEL	M3f2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHzfY9KSzVyPUWuO\|I3OjdizszN	MWXTRW5ITVJ?
BL-41	M3uzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELob\|BKSzVyPUWuPFEzPjZizszN	MnjlV2FPT0WU
WM-115	M1L1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTVwOEG1NFkh\|ryP	MmnsV2FPT0WU
SK-MEL-2	M16yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HUTGlEPTB;Nj6zPFM1PCEQvF2=	MVzTRW5ITVJ?
CGTH-W-1	NVPhWoFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFz3W3VKSzVyPU[uOFE4KM7:TR?=	NI\oenRUSU6JRWK=
BB65-RCC	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPz[I9tUUN3ME22MlU{OTl3IN88US=>	MnjKV2FPT0WU
CAL-85-1	NXLnW5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTZwNkC5N\|Yh\|ryP	MlLhV2FPT0WU
RT-112	M1;rR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7iepRIUUN3ME23MlE3PDV4IN88US=>	MoTjV2FPT0WU
MC116	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTdwMki2PVEh\|ryP	NEThV4pUSU6JRWK=
G-361	NEjiU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTwV5lKSzVyPUeuOFY2PjFizszN	MW\TRW5ITVJ?
SW1417	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTdwNkS1PFQh\|ryP	M3jW[XNCVkeHUh?=
MV-4-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3QXmZKSzVyPUiuOVQ{ODRizszN	NXfy[lZlW0GQR1XS
CAL-72	NGPFcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fDfGlEPTB;OD63OlEyOyEQvF2=	NET1N4tUSU6JRWK=
MKN28	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTqPGpKSzVyPUiuPFg2OTZizszN	M33RT3NCVkeHUh?=
MEG-01	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;1eZV6UUN3ME24Mlk6ODR\|IN88US=>	MlLsV2FPT0WU
ACHN	NF7Ye\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;uTWM2OD17LkOwOVQ3KM7:TR?=	M4nVfnNCVkeHUh?=
NCI-H1755	NVP1PWJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTlwM{m5PFYh\|ryP	MnvpV2FPT0WU
NCI-H64	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTlwNEKyOVUh\|ryP	NUnydopTW0GQR1XS
COLO-205	NY\Q[5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn36TWM2OD17LkSzPFIyKM7:TR?=	M1jSdHNCVkeHUh?=
CTV-1	M1HvbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnj3TWM2OD17LkSzPFk1KM7:TR?=	MVHTRW5ITVJ?
U-2-OS	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1K1RmlEPTB;OT60OVAxPiEQvF2=	NVjOSWc3W0GQR1XS
LB996-RCC	M1jaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTlwNUKzPVch\|ryP	MUPTRW5ITVJ?
SK-N-DZ	NHfqRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn4[XJ{UUN3ME25MlY2PzR{IN88US=>	M2PjZ3NCVkeHUh?=
EFM-19	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\CTWM2OD17Lke1OVY3KM7:TR?=	NHfQPIdUSU6JRWK=
DBTRG-05MG	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTNT4E6UUN3ME25Mlc4PzdizszN	MljHV2FPT0WU
U-118-MG	MmrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHuxboxKSzVyPUmuPVQ1PDRizszN	MlLQV2FPT0WU
LB1047-RCC	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmi3TWM2OD17Lkm5O\|k5KM7:TR?=	Mn\hV2FPT0WU
NCI-H28	M2\KZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfFV5VKSzVyPUGwMlQ1OTNizszN	NXTaPIwzW0GQR1XS
MZ2-MEL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTFyLkS2O\|ch\|ryP	MXHTRW5ITVJ?
M059J	M{THNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEKzWY1KSzVyPUGwMlYyODJizszN	NFziUYhUSU6JRWK=
HT-3	NH3jfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTFyLk[xO\|kh\|ryP	NYrvSIZHW0GQR1XS
SNU-387	M1u2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnrendKSzVyPUGwMlczOzVizszN	NFLJT2pUSU6JRWK=
NCI-H526	NF3tdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\WVppSUUN3ME2xNU4yOzZ3IN88US=>	M3SwZ3NCVkeHUh?=
HEL	M37Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjWRYpKSzVyPUGxMlY2PzlizszN	MYrTRW5ITVJ?
PA-1	Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoCyTWM2OD1zMT65N{DPxE1?	M4qwTXNCVkeHUh?=
PC-14	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M335R2lEPTB;MUKuN\|I1KM7:TR?=	MXXTRW5ITVJ?
C8166	Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\EUmlEPTB;MUOuNlMyQCEQvF2=	M1TYO3NCVkeHUh?=
NCI-H82	NFeyfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fzPGlEPTB;MUOuNlkxQSEQvF2=	MUTTRW5ITVJ?
DSH1	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vLbWlEPTB;MUOuN\|g4QSEQvF2=	Mn63V2FPT0WU
T98G	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nReWlEPTB;MUOuOFcyPyEQvF2=	MlrzV2FPT0WU
KU812	MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTF\|LkWxO\|Uh\|ryP	M{fLSnNCVkeHUh?=
SW48	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[5[WlEPTB;MUOuO\|I3PSEQvF2=	M2TIRnNCVkeHUh?=
MEL-HO	NIL5ZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn:yTWM2OD1zMz64PFI6KM7:TR?=	NXTLbJAyW0GQR1XS
SF539	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnpTWM2OD1zND6wNVE3KM7:TR?=	MYDTRW5ITVJ?
NB1	NELvSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2D6VGlEPTB;MUSuNVk{PSEQvF2=	MUnTRW5ITVJ?
ST486	NHvpeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M333OGlEPTB;MUSuNlI2OSEQvF2=	MUfTRW5ITVJ?
LoVo	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ftTGlEPTB;MUWuNlY2QSEQvF2=	MonCV2FPT0WU
NH-12	NFPLeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Hw[mlEPTB;MU[uNFA6PyEQvF2=	MWfTRW5ITVJ?
CCRF-CEM	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fQdmlEPTB;MU[uOlcxOiEQvF2=	MlHSV2FPT0WU
Daudi	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTF5Lk[xOFkh\|ryP	M37EW3NCVkeHUh?=
SIMA	NXXDdYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF5LkmxNVgh\|ryP	NWnLOGxzW0GQR1XS
8305C	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVW5cIwxUUN3ME2xPE42OzB3IN88US=>	MWTTRW5ITVJ?
EM-2	NYfWdmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHVTWM2OD1zOD62NlQ5KM7:TR?=	NXX1cWRoW0GQR1XS
SNU-449	NGLoSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G1SmlEPTB;MUiuO\|E2KM7:TR?=	M1TTdHNCVkeHUh?=
A101D	NV;0[ZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGi4eWpKSzVyPUG5MlI1OyEQvF2=	NECzfGNUSU6JRWK=
MHH-NB-11	NILNdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;OXYQ2UUN3ME2xPU42OzR{IN88US=>	NGqye5hUSU6JRWK=
Becker	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7Ie4c3UUN3ME2yNE4yPzd5IN88US=>	MWXTRW5ITVJ?
NCI-H727	NH3BR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\xV4JMUUN3ME2yNE4zOTZ7IN88US=>	MnnjV2FPT0WU
HCC1187	NHHzV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYn5WWFqUUN3ME2yNE4{PTh7IN88US=>	NFrqbFBUSU6JRWK=
KYSE-450	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfkRmVZUUN3ME2yNU42OzV2IN88US=>	MoXJV2FPT0WU
SK-MEL-28	NG[1WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TOZ2lEPTB;MkGuOlg3OyEQvF2=	NYPS[2FPW0GQR1XS
BPH-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfOTWM2OD1{MT63NFM2KM7:TR?=	M4X4fnNCVkeHUh?=
EoL-1-	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLaTWM2OD1{MT64N\|g2KM7:TR?=	MX3TRW5ITVJ?
TGBC24TKB	M4LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3GTWM2OD1{MT64PVU4KM7:TR?=	MkjSV2FPT0WU
KARPAS-299	NYnOWGRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfkWm1KSzVyPUKyMlE6PTRizszN	NVPlSJpKW0GQR1XS
SW684	M3Lscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkX5TWM2OD1{Mj6yPFU5KM7:TR?=	NWqwd5JXW0GQR1XS
RXF393	NVO5XoI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLyWllKSzVyPUKyMlYxPjhizszN	MYPTRW5ITVJ?
LS-513	M3zmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7XXm1KSzVyPUKyMlYyQTJizszN	M3HwR3NCVkeHUh?=
KURAMOCHI	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrpPWtzUUN3ME2yNk44ODZ7IN88US=>	M3\CNHNCVkeHUh?=
GI-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTJ{Lke4OFEh\|ryP	NX2wRlBrW0GQR1XS
M14	NH3leGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr2Z3hOUUN3ME2yN{4yOTN{IN88US=>	NITq[lRUSU6JRWK=
REH	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHvSoVwUUN3ME2yN{4yPjl7IN88US=>	NVfUcFRsW0GQR1XS
K5	M4LzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTCTVBGUUN3ME2yN{42PDh4IN88US=>	M17jSHNCVkeHUh?=
PANC-10-05	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHnTWM2OD1{ND6wPFk5KM7:TR?=	MYDTRW5ITVJ?
HMV-II	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XaR2lEPTB;MkSuNlE3OyEQvF2=	MnrzV2FPT0WU
NCI-H1963	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTJ2LkK4N\|kh\|ryP	NFzIV5JUSU6JRWK=
LU-139	M2XHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1n6e2lEPTB;MkSuPFM2KM7:TR?=	M1m5UHNCVkeHUh?=
KASUMI-1	MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHJTWM2OD1{ND65N\|I5KM7:TR?=	M3;ZfXNCVkeHUh?=
RO82-W-1	NILGTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTJ4LkezO\|ch\|ryP	NHjUR4pUSU6JRWK=
NCI-H1770	NWLESIZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJ4Lki5PFYh\|ryP	NUDkZnhUW0GQR1XS
SNG-M	M2rQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJ5LkKyO\|Eh\|ryP	NEDqXXJUSU6JRWK=
KLE	M1\uUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTSTWM2OD1{Nz6yOVY2KM7:TR?=	M1;ubnNCVkeHUh?=
NCI-H2170	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;tfmlEPTB;MkeuOVI5OiEQvF2=	NXvyU\|BJW0GQR1XS
COLO-792	NFfRPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fafmlEPTB;MkeuO\|czQCEQvF2=	MXrTRW5ITVJ?
ES8	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX2zWGtlUUN3ME2yO{44QDF2IN88US=>	NGXQenpUSU6JRWK=
MC-CAR	MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHJXIZUUUN3ME2yO{44QTB5IN88US=>	M{\ZcHNCVkeHUh?=
SU-DHL-1	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTJ5Lkm0O\|Qh\|ryP	M4DreXNCVkeHUh?=
OAW-28	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlK1TWM2OD1{OD6wNFUzKM7:TR?=	NILvN5ZUSU6JRWK=
C32	MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTJ6LkC4NlYh\|ryP	M4jDWHNCVkeHUh?=
SW872	M{LySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTJ6LkWzNlYh\|ryP	M3:1ZXNCVkeHUh?=
JiyoyeP-2003	NGPTeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJ7Lk[3NVkh\|ryP	NV3rSohYW0GQR1XS
A204	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTTToJKSzVyPUK5MlY5OjhizszN	MmXGV2FPT0WU
IST-MES1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jHbGlEPTB;MkmuO\|A6OiEQvF2=	M{jnRnNCVkeHUh?=
LCLC-103H	M1HBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTNyLkKwOVkh\|ryP	NIK2foJUSU6JRWK=
CAKI-1	NITwN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrYTWM2OD1\|MD6yOlU3KM7:TR?=	MojBV2FPT0WU
NALM-6	NHPIXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LiemlEPTB;M{CuOFk3PSEQvF2=	MUXTRW5ITVJ?
SK-MM-2	NYTLV\|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTrfFhKSzVyPUOwMlk4QTJizszN	NILhOXBUSU6JRWK=
LB373-MEL-D	M2HhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTNzLkCwOFch\|ryP	NVfsbpRNW0GQR1XS
CAS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTYTWM2OD1\|MT63OlY2KM7:TR?=	M1;3dHNCVkeHUh?=
KNS-42	M2fnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1[yUmlEPTB;M{GuPFY3OiEQvF2=	MlPuV2FPT0WU
SW948	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDP[IRKSzVyPUOyMlc2PDhizszN	MUfTRW5ITVJ?
HCC1143	NYfjXYp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rxOWlEPTB;M{KuO\|k4QSEQvF2=	NIHBT4pUSU6JRWK=
NCI-H1648	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXyPG1KSzVyPUOyMlg1PjdizszN	NYDsUVlNW0GQR1XS
RVH-421	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D5U2lEPTB;M{OuNVY5KM7:TR?=	Mnr2V2FPT0WU
KU-19-19	NVvVWnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nlTmlEPTB;M{OuO\|U{PCEQvF2=	MULTRW5ITVJ?
PFSK-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\TTWM2OD1\|ND65NlQyKM7:TR?=	NVPnOmhKW0GQR1XS
TK10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DIVGlEPTB;M{WuNVMzOiEQvF2=	M4DNfHNCVkeHUh?=
IGROV-1	M1\m[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTN3LkO0NVYh\|ryP	NGe5OGtUSU6JRWK=
EFE-184	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnaZnBDUUN3ME2zOU46OTdizszN	NX72ZW02W0GQR1XS
8505C	NGLGSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTN3LkmyPVQh\|ryP	NYDTNmNWW0GQR1XS
SK-UT-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzLTWM2OD1\|Nj6zN\|MyKM7:TR?=	NELyZ4xUSU6JRWK=
MKN1	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PDWWlEPTB;M{[uPFQ1PCEQvF2=	M{HFZnNCVkeHUh?=
no-10	NXH4So97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vOOmlEPTB;M{iuNVI6PCEQvF2=	NUXwWHRoW0GQR1XS
HT-144	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XtcWlEPTB;M{iuNlU4PSEQvF2=	NWDTSIRFW0GQR1XS
CMK	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTN6LkSxOlIh\|ryP	M2LPdHNCVkeHUh?=
KM12	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjRTWM2OD1\|OD61PVk5KM7:TR?=	MnzUV2FPT0WU
HCC2218	NGThUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TvU2lEPTB;NECuOVg1QSEQvF2=	MkjVV2FPT0WU
BE-13	NVLh[VdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLyTWM2OD12MT60OFc{KM7:TR?=	NULMTI1{W0GQR1XS
SK-CO-1	NVizRYszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjOUFFJUUN3ME20NU44PzV3IN88US=>	NFfnNVRUSU6JRWK=
MPP-89	M3\xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTRzLkmyNVEh\|ryP	M17wZ3NCVkeHUh?=
NY	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTR{LkG4NFEh\|ryP	NH3UbndUSU6JRWK=
IST-MEL1	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLZTWM2OD12Mj62PVM5KM7:TR?=	MnP5V2FPT0WU
HCT-116	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTwe3NEUUN3ME20N{4zODl7IN88US=>	M3PEcHNCVkeHUh?=
LB831-BLC	M4H2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO2VXZKSzVyPUSzMlY6PyEQvF2=	NEf5dIlUSU6JRWK=
TE-8	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPISnpKSzVyPUSzMlc5QTVizszN	Mlv0V2FPT0WU
SR	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHoTWM2OD12Mz64Olc{KM7:TR?=	M4XJcHNCVkeHUh?=
ESS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DvbmlEPTB;NESuNlA3OiEQvF2=	M3TkOXNCVkeHUh?=
KYSE-270	NHq0WolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTR3LkC0N\|ch\|ryP	M1jteXNCVkeHUh?=
H4	NVjQcVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTR3LkOyPVYh\|ryP	MULTRW5ITVJ?
COLO-800	M4HPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPoWpVKSzVyPUS1MlU5QThizszN	MWnTRW5ITVJ?
Ramos-2G6-4C10	NFuyTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITRbIZKSzVyPUS2MlA4PTVizszN	MVfTRW5ITVJ?
no-11	M4iyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7veHZKSzVyPUS2MlIxOzFizszN	M1PnbnNCVkeHUh?=
UACC-62	NXnLdHFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrETWM2OD12Nj64OlA5KM7:TR?=	NVq1VI5mW0GQR1XS
D-542MG	NUDifHIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXBXWQ5UUN3ME20O{41PTh7IN88US=>	M1nhNXNCVkeHUh?=
NCI-H747	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDMTWM2OD12Nz63NlY1KM7:TR?=	M4jwe3NCVkeHUh?=
HCC2998	NITIV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTkenBLUUN3ME20PE4zQTh{IN88US=>	NHjmRZFUSU6JRWK=
SNB75	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33HZmlEPTB;NEiuOFEyQCEQvF2=	MXvTRW5ITVJ?
COR-L105	MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvQTWM2OD12OD65O\|Mh\|ryP	M1LOTnNCVkeHUh?=
SNU-C1	NH3iOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrqR5lJUUN3ME20PU4{OjB5IN88US=>	NWq4c2szW0GQR1XS
LC4-1	NG[ydoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjrWXpKSzVyPUS5Mlg6OTJizszN	NIfsXVFUSU6JRWK=
KS-1	MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTVyLkKyNlUh\|ryP	M3rpWHNCVkeHUh?=
NCI-H1793	NUTiVpRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH0NIdHUUN3ME21NU4zOzFizszN	NUfvWIJqW0GQR1XS
NCI-H1650	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDHSJVKSzVyPUWxMlU5PDlizszN	Mk\wV2FPT0WU
MCF7	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTSTWM2OD13MT63OVU1KM7:TR?=	NUOzd4k6W0GQR1XS
SK-N-AS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;HdmlEPTB;NUGuPFI5OSEQvF2=	MmHsV2FPT0WU
SW837	MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEG1OFBKSzVyPUWxMlk4QDVizszN	NWnKVpNIW0GQR1XS
DB	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrXT2VzUUN3ME21NU46QDV3IN88US=>	NXK3OmxHW0GQR1XS
CESS	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlKxTWM2OD13Mj6xOFUh\|ryP	MX;TRW5ITVJ?
CHP-126	M4rFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDXZ5hKSzVyPUWzMlUyPjlizszN	NF3qUWZUSU6JRWK=
COLO-824	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHrTWM2OD13Mz62PVc3KM7:TR?=	NV\mNJNGW0GQR1XS
MG-63	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlz4TWM2OD13Mz65N\|gyKM7:TR?=	MXrTRW5ITVJ?
KGN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPFR4ZPUUN3ME21N{46PTlizszN	MVzTRW5ITVJ?
697	MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu4VW46UUN3ME21OE4yPTV3IN88US=>	NU\iOYNjW0GQR1XS
MC-IXC	NGXlbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvNbXFKSzVyPUW0MlQ{PjRizszN	NGXtRYhUSU6JRWK=
A375	M3:3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXyzVFhlUUN3ME21OE45ODV7IN88US=>	M{OwTHNCVkeHUh?=
LXF-289	M2Dodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPyRlVKSzVyPUW1MlUxPjZizszN	NUPiUmNuW0GQR1XS
ES6	NF7oTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXju[WdnUUN3ME21OU45QDl7IN88US=>	MXzTRW5ITVJ?
DV-90	M{TWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XZPWlEPTB;NUWuPFkyPyEQvF2=	M33Ze3NCVkeHUh?=
RCM-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnPXmVKSzVyPUW2MlAxPzhizszN	M3;2WXNCVkeHUh?=
NCI-H2405	NWXad\|hTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PremlEPTB;NU[uNVY6OyEQvF2=	Mn;MV2FPT0WU
DoTc2-4510	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXnTWM2OD13Nj62NFU4KM7:TR?=	M4SxXHNCVkeHUh?=
RPMI-8866	NEfiVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXKzVJdXUUN3ME21O{4zPDF{IN88US=>	MoPBV2FPT0WU
BV-173	M1nLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTV5LkWxOFIh\|ryP	MlvFV2FPT0WU
LCLC-97TM1	M2Ptdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPaTm1GUUN3ME21PU4xPTV\|IN88US=>	MmnNV2FPT0WU
HT-1376	NXzIW4lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;0eJJMUUN3ME21PU4xQTJzIN88US=>	MnX5V2FPT0WU
ACN	NXTUW\|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nSeWlEPTB;NUmuNVU5PyEQvF2=	MUfTRW5ITVJ?
LU-134-A	NGT0T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTV7Lk[wNVYh\|ryP	NXvJW49sW0GQR1XS
SiHa	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPlZmF4UUN3ME21PU43PDh5IN88US=>	MnL4V2FPT0WU
EKVX	NVHufVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M360WWlEPTB;NkGuOFk2QCEQvF2=	NYPmTmZOW0GQR1XS
NMC-G1	NXv2S\|BFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfYUo01UUN3ME22NU46OjR{IN88US=>	NV\0SG9LW0GQR1XS
NCI-H1734	Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTZzLkm2OlMh\|ryP	MUfTRW5ITVJ?
K-562	NEXJfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnpNlhKSzVyPU[yMlI1PTJizszN	M2TPXnNCVkeHUh?=
T-24	M3THU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[wTWM2OD14Mj63NVI3KM7:TR?=	NYfwXW4yW0GQR1XS
SCH	M{jNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2raR2lEPTB;NkSuNlM2OSEQvF2=	MljuV2FPT0WU
AN3-CA	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTBTWM2OD14ND6zNFM2KM7:TR?=	MlvqV2FPT0WU
MFE-296	NGPQb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LRdmlEPTB;NkSuOFQ4OyEQvF2=	MlmwV2FPT0WU
HuCCT1	M{H6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3[zZWlEPTB;NkeuNFM4PCEQvF2=	MVTTRW5ITVJ?
NCI-H1703	NHXDPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTZ6LkGxO\|Eh\|ryP	NUPTdoxKW0GQR1XS
C-4-II	NWLxfVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTZ7LkO2NFch\|ryP	NXHFdJpDW0GQR1XS
NCI-H2342	NXLmTW5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrvNHpiUUN3ME22PU4{QTZzIN88US=>	NYrsOIxSW0GQR1XS
Hs-578-T	NETmd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV72OoZ6UUN3ME23NE4{KM7:TR?=	NIDlSpRUSU6JRWK=
HCC1806	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXWwZphYUUN3ME23NU41PTh5IN88US=>	M3zJOXNCVkeHUh?=
EW-16	NU\kRWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTTe\|FOUUN3ME23NU44PDF3IN88US=>	MWTTRW5ITVJ?
KALS-1	NV21cJR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTd\|LkW0O\|Uh\|ryP	NUjqPI9HW0GQR1XS
RT4	MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTd\|LkW3OFIh\|ryP	NEHMO5JUSU6JRWK=
LS-411N	NE\FUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTd2LkK1Nlgh\|ryP	NEHPblFUSU6JRWK=
SK-MEL-1	NU\EOo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3mzb2lEPTB;N{WuPFAyQSEQvF2=	NEK4NYhUSU6JRWK=
8-MG-BA	M1jSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnG[GNKSzVyPUe2MlExQTZizszN	MXPTRW5ITVJ?
HSC-3	M4LX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTd5LkCyPFIh\|ryP	MYTTRW5ITVJ?
NB6	M3LnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3z0eWlEPTB;N{iuNVI6QSEQvF2=	NWnidYJqW0GQR1XS
PANC-03-27	M4nSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnlUpRKSzVyPUe4MlQ{PSEQvF2=	MoLvV2FPT0WU
KP-N-YS	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fQXGlEPTB;N{iuOVg4QCEQvF2=	MkT6V2FPT0WU
SF295	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3tS4RjUUN3ME23PU46PTV\|IN88US=>	NGfqN4JUSU6JRWK=
HCE-T	NYDue2FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvvbIVVUUN3ME24NE4yPTh6IN88US=>	NY\VdVd2W0GQR1XS
KYSE-410	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2r0c2lEPTB;OECuNlg2PyEQvF2=	NEHQNWZUSU6JRWK=
NB12	NEHwVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRThyLkmzOlkh\|ryP	MnTtV2FPT0WU
NCI-H661	NEPvSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorwTWM2OD16MT6zOFQh\|ryP	M1fzUXNCVkeHUh?=
NCI-H1417	NITaVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;zTWM2OD16MT60N\|Y5KM7:TR?=	NWfYe45VW0GQR1XS
KMOE-2	MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz1NIpXUUN3ME24NU45PTNzIN88US=>	NXGwUJlNW0GQR1XS
SW1573	NWPVV4I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLsTWM2OD16Mj61PFk{KM7:TR?=	NFLx[VdUSU6JRWK=
BFTC-905	NXPXW\|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2T5R2lEPTB;OESuNFE4OiEQvF2=	NXPTNnFLW0GQR1XS
SBC-1	NXXQUnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TsdGlEPTB;OESuNFIxQCEQvF2=	MkWwV2FPT0WU
MDA-MB-175-VII	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTh3Lke0NlYh\|ryP	NU\sOmFNW0GQR1XS
TE-12	NIfzSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTHOGZRUUN3ME24PU4{PzRzIN88US=>	NYDTcplGW0GQR1XS
NCI-H650	NUTFSGhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTh7Lki3NlQh\|ryP	NWjvWWNFW0GQR1XS
C-33-A	NUD4WpRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\xeo5DUUN3ME25NE42PCEQvF2=	NHjQWolUSU6JRWK=
MZ7-mel	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEmxVJZKSzVyPUmxMlI3PzZizszN	MlSwV2FPT0WU
BOKU	M{HWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUntUIVLUUN3ME25Nk43QTV5IN88US=>	MUnTRW5ITVJ?
CAL-33	MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrGU4xKSzVyPUmzMlA3ODFizszN	MkTBV2FPT0WU
23132-87	NIXwfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPHTWM2OD17Mz6xOlgh\|ryP	M{DlbHNCVkeHUh?=
J82	NXnDbot6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Lud2lEPTB;OUOuO\|gyOSEQvF2=	NH\oOotUSU6JRWK=
MZ1-PC	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfz[VJWUUN3ME25OE42QTh2IN88US=>	MnPyV2FPT0WU
MEL-JUSO	NGPjbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXnTWM2OD17ND65OVQh\|ryP	NYDyXWZ1W0GQR1XS
RMG-I	NWfTdZozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHKbIVKSzVyPUm1MlExPzJizszN	NIO2NJpUSU6JRWK=
A2058	M1W3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHnS41WUUN3ME25OU41PjF5IN88US=>	MUDTRW5ITVJ?
Caov-4	NFHrTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIC1eWNKSzVyPUm1MlY5PSEQvF2=	NELZWHNUSU6JRWK=
OS-RC-2	NGLTN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\1W25JUUN3ME25O{41PjFizszN	Ml;KV2FPT0WU
MKN7	NVK1[I1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrQTWM2OD17Nz63OFM6KM7:TR?=	M2DKWXNCVkeHUh?=
U-698-M	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnrZoJKSzVyPUm4Mlk1QDlizszN	M{i1S3NCVkeHUh?=
PC-3	NIe4S2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTl7LkC1OlQh\|ryP	NH\PeVNUSU6JRWK=
NCI-H292	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\t[mlEPTB;OUmuN\|AxPCEQvF2=	M1fPWXNCVkeHUh?=
IGR-1	NV;neFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3TTWM2OD17OT6zNVE6KM7:TR?=	NILIcHRUSU6JRWK=
Mewo	NEjtZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nOe2lEPTB;OUmuOVYxOyEQvF2=	MmPFV2FPT0WU
LU-65	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1PD[WlEPTB;MUCxMlA5OSEQvF2=	MmPNV2FPT0WU
Saos-2	NES4bWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTSbWhSUUN3ME2xNFEvPDN5IN88US=>	MnnRV2FPT0WU
TE-11	M4KxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq4N25KSzVyPUGwNU44OjRizszN	MV\TRW5ITVJ?
SK-MES-1	M2nVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPsTWM2OD1zMEGuO\|YzKM7:TR?=	MWnTRW5ITVJ?
KE-37	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Pad2lEPTB;MUCyMlk2KM7:TR?=	MWHTRW5ITVJ?
MKN45	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjodVgyUUN3ME2xNFMvPTh2IN88US=>	MXvTRW5ITVJ?
UM-UC-3	M37zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlL1TWM2OD1zMEOuPFQzKM7:TR?=	NVfmTpU5W0GQR1XS
SNU-C2B	M{\OeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnWxTWM2OD1zMEWuNFI{KM7:TR?=	NIXxfmpUSU6JRWK=
RPMI-8226	NXzWb5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTFyNj62O\|gh\|ryP	NHnEe2dUSU6JRWK=
PANC-08-13	NH;pcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPQTpBKSzVyPUGwOk45PSEQvF2=	MmTmV2FPT0WU
NCI-H23	M1TPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILicGNKSzVyPUGwPE4{PTdizszN	NUe4NVN1W0GQR1XS
HOP-92	NUPKSG9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\6TWM2OD1zMEiuOFc2KM7:TR?=	NHPORW9USU6JRWK=
FTC-133	MojxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2j6XWlEPTB;MUC4MlQ5QCEQvF2=	MnTvV2FPT0WU
D-263MG	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jLZWlEPTB;MUC4Mlk3OSEQvF2=	MmrOV2FPT0WU
DU-145	M4j4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL2TWM2OD1zMEmuPVQ2KM7:TR?=	NH7pbHpUSU6JRWK=
A253	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknhTWM2OD1zMUCuOFc6KM7:TR?=	MnfKV2FPT0WU
HCT-15	NV[zNI95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFzMD62OlEh\|ryP	NF\uXIFUSU6JRWK=
WSU-NHL	NIP0S3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjZSoN{UUN3ME2xNVIvODFizszN	MnHrV2FPT0WU
U031	NV;CZnM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTZV3p7UUN3ME2xNVIvODZ3IN88US=>	NGTVfY9USU6JRWK=
MDA-MB-157	NUj5XpZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfRTWM2OD1zMUKuOFkh\|ryP	M1jXbXNCVkeHUh?=
NEC8	NVTGSoF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPIOnRKSzVyPUGxNk43OjRizszN	NUfvOZFiW0GQR1XS
SIG-M5	NX7iNYpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFzMz6xNlUh\|ryP	M2i1bnNCVkeHUh?=
786-0	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7iPIZKSzVyPUGxN{41PTNizszN	NUHLUFZFW0GQR1XS
DMS-273	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFzNT62NVch\|ryP	NELMN3hUSU6JRWK=
Calu-6	NHHVN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfITWM2OD1zMU[uO\|k5KM7:TR?=	NED0flZUSU6JRWK=
HCC1599	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlK5TWM2OD1zMUeuNVU3KM7:TR?=	NXPEeHZpW0GQR1XS
OVCAR-8	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFzNz62Olgh\|ryP	MUTTRW5ITVJ?
ATN-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jqNGlEPTB;MUG3MlgzQCEQvF2=	NXvjemxtW0GQR1XS
RKO	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fjeWlEPTB;MUG3Mlg6QCEQvF2=	NFHlV4FUSU6JRWK=
SKG-IIIa	M{Lme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLRfppKSzVyPUGxPE4yOTZizszN	NV;tUlA2W0GQR1XS
SUP-T1	MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTFzOD65OVYh\|ryP	NFvaWmFUSU6JRWK=
KNS-81-FD	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFzOT60NVch\|ryP	MnjTV2FPT0WU
OVCAR-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFzOT65NVUh\|ryP	M37MXnNCVkeHUh?=
NCI-N87	NF62e\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTF{MT6wOFQh\|ryP	M3zPTnNCVkeHUh?=
HuP-T4	NWPVXolPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\uUHNKSzVyPUGyNU42PSEQvF2=	MWrTRW5ITVJ?
KYSE-140	MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nrZWlEPTB;MUKyMlE1OSEQvF2=	MWHTRW5ITVJ?
HAL-01	NVX6OG1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF{Mj60PVkh\|ryP	MkjKV2FPT0WU
HT-29	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVv6TG1NUUN3ME2xNlIvPzd6IN88US=>	MlHXV2FPT0WU
OPM-2	NXXSNIdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITZUWJKSzVyPUGyN{4yPzZizszN	M4KzZXNCVkeHUh?=
SW1463	NX[zbZlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTF{ND6wO\|ch\|ryP	M1zSRXNCVkeHUh?=
NCI-H2087	NWH1[3dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nvRWlEPTB;MUK0MlI5OyEQvF2=	NVTwRXlYW0GQR1XS
UMC-11	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTF{Nj6wN\|gh\|ryP	NXuy[40{W0GQR1XS
EB-3	NWTrcFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPoVWdKSzVyPUGyO{4xOTNizszN	NGjifIpUSU6JRWK=
HEC-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HrO2lEPTB;MUK5MlE6QCEQvF2=	NIPVbGRUSU6JRWK=
LU-99A	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTYTWM2OD1zMkmuPVMyKM7:TR?=	MkfCV2FPT0WU
VMRC-RCZ	Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfZTWM2OD1zM{CuN\|c2KM7:TR?=	Mn6yV2FPT0WU
MFH-ino	NHXRToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvSTWM2OD1zM{GuNVE1KM7:TR?=	Mlu5V2FPT0WU
HT-1080	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXNTWM2OD1zM{KuNlA1KM7:TR?=	M4PWOHNCVkeHUh?=
CTB-1	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzSTWM2OD1zM{KuPFk4KM7:TR?=	M4T1VnNCVkeHUh?=
Capan-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f5N2lEPTB;MUOzMlk4PSEQvF2=	MVPTRW5ITVJ?
BB30-HNC	NVzrSmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHq[o1KSzVyPUGzOE4yOTZizszN	MXfTRW5ITVJ?
CP50-MEL-B	M1[0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDiTWM2OD1zM{SuNkDPxE1?	MXzTRW5ITVJ?
JEG-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1e2T2lEPTB;MUO0MlM2QSEQvF2=	NWLC[VloW0GQR1XS
NCI-H1437	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLqTWM2OD1zM{SuOVkh\|ryP	NW\3O2tmW0GQR1XS
NOS-1	M4nDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4i3UGlEPTB;MUO0Mlc3PSEQvF2=	NWHnWHF[W0GQR1XS
G-402	NH3KZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzH[VBKSzVyPUGzOU4zQTVizszN	NUHQ[3hSW0GQR1XS
OAW-42	MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTF\|Nz64OVYh\|ryP	NI\pcnJUSU6JRWK=
Ca-Ski	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnrVZU6UUN3ME2xN\|gvQDNzIN88US=>	NFPEe25USU6JRWK=
BHT-101	NULVZ5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF2MD6yNFgh\|ryP	NWrZTJh[W0GQR1XS
OVCAR-4	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjnN4JMUUN3ME2xOFAvPzR7IN88US=>	M1XKRnNCVkeHUh?=
Detroit562	M4jnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4myU2lEPTB;MUSxMlQ3PiEQvF2=	MYPTRW5ITVJ?
OCI-AML2	NGLXdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nXUGlEPTB;MUSxMlUxPyEQvF2=	NX[5c2F1W0GQR1XS
OE33	NF\Se2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLkTWM2OD1zNEGuO\|k5KM7:TR?=	NGLnZ4tUSU6JRWK=
YKG-1	NEDpfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkC5TWM2OD1zNEKuPFg6KM7:TR?=	NEK4e4JUSU6JRWK=
CCF-STTG1	NFvJ[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF2Mz6zN\|Qh\|ryP	NWLnWHlvW0GQR1XS
NCI-H810	MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvJTWM2OD1zNEOuOlg4KM7:TR?=	M3TmN3NCVkeHUh?=
SCC-25	NHz2[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLDVXVKSzVyPUG0OE4xODVizszN	Mlz3V2FPT0WU
HTC-C3	NHjaWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\GRm1KSzVyPUG0OU4xPzVizszN	M{\u[3NCVkeHUh?=
G-401	M2LGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4D5PGlEPTB;MUS1Mlg{PSEQvF2=	NUT0UXlSW0GQR1XS
OMC-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny4TWM2OD1zNEWuPVY4KM7:TR?=	NV7FU3N1W0GQR1XS
LK-2	NYjzbo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HnPWlEPTB;MUS3MlE1OyEQvF2=	NG\WToxUSU6JRWK=
SW13	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnHNYFoUUN3ME2xOFcvOjV\|IN88US=>	NEXnZ2VUSU6JRWK=
BB49-HNC	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoiyTWM2OD1zNEeuOFA1KM7:TR?=	NIHEW5FUSU6JRWK=
DMS-114	NVj6cG9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjxRXd3UUN3ME2xOFcvPDRzIN88US=>	NH\XPXhUSU6JRWK=
GCIY	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTENXJWUUN3ME2xOFcvPzl5IN88US=>	M1;4O3NCVkeHUh?=
GAMG	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jOPGlEPTB;MUS4MlI1PyEQvF2=	M3fSWnNCVkeHUh?=
KYSE-520	M3Wzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnHTWM2OD1zNEiuOVQh\|ryP	MkiyV2FPT0WU
LB647-SCLC	M2ThN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTF2OD61OlIh\|ryP	M{HnUnNCVkeHUh?=
639-V	M{C0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWC4WlNEUUN3ME2xOFgvPzB3IN88US=>	NXzZ[Hh3W0GQR1XS
TE-9	NFPU[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2r3W2lEPTB;MUS5MlQ1OyEQvF2=	NUTxOo5GW0GQR1XS
Caov-3	NXXz[oZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTF2OT63NVQh\|ryP	NGHTfopUSU6JRWK=
L-540	NEPhXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\zSW1LUUN3ME2xOFkvPzVizszN	NFfDbHZUSU6JRWK=
NCI-H748	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTF3MD6yNFkh\|ryP	MlKxV2FPT0WU
GDM-1	NHv3PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfycFFKSzVyPUG1NU4yOzVizszN	M1:y[3NCVkeHUh?=
GAK	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{[4NWlEPTB;MUWxMlM4PCEQvF2=	NIO5WpNUSU6JRWK=
AsPC-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvZTVVPUUN3ME2xOVIvPzZ2IN88US=>	MV\TRW5ITVJ?
MDA-MB-361	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHi3d21KSzVyPUG1N{4yPjRizszN	MnjWV2FPT0WU
TT	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLVTWM2OD1zNUOuOFkh\|ryP	MX3TRW5ITVJ?
Calu-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\aTWM2OD1zNUSuNFA{KM7:TR?=	NEnFSY5USU6JRWK=
RERF-LC-MS	NVizVJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH:5SldKSzVyPUG1OE44PzJizszN	Mk\PV2FPT0WU
DK-MG	NY\jNYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XKOGlEPTB;MUW1MlE5OyEQvF2=	NYjyZZg{W0GQR1XS
CAL-120	NFjvVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv6TZhFUUN3ME2xOVUvQDJzIN88US=>	MnfDV2FPT0WU
HCC1419	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYTwNYxmUUN3ME2xOVYvODd5IN88US=>	MlvHV2FPT0WU
DG-75	NWnTW3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTF3Nj62PVQh\|ryP	MknZV2FPT0WU
HCC38	NVq3bVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTF3Nz6zOlkh\|ryP	NVm4VXNzW0GQR1XS
HCC70	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LLbGlEPTB;MUW5MlI1OiEQvF2=	NHrrdHhUSU6JRWK=
ES4	NIrPZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDETIhxUUN3ME2xOVkvOzl4IN88US=>	NH33XItUSU6JRWK=
NCI-H2052	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{D1VWlEPTB;MUW5MlU5OyEQvF2=	NICyN2hUSU6JRWK=
EFO-27	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;pSHgyUUN3ME2xOlAvPTh2IN88US=>	NYTBSmRsW0GQR1XS
CAL-62	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDCTWM2OD1zNkKuOlE{KM7:TR?=	NFLBeIhUSU6JRWK=
CHP-212	M3W5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF4Mz62NlYh\|ryP	M{PGUXNCVkeHUh?=
AU565	NE\ERlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTF4Mz62OEDPxE1?	NHvjNHpUSU6JRWK=
Ca9-22	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPOeVF1UUN3ME2xOlQvOzJzIN88US=>	MXjTRW5ITVJ?
EFO-21	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF4NT60OUDPxE1?	NUHOVW82W0GQR1XS
KINGS-1	NGS1O3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nnUmlEPTB;MU[3MlM2PCEQvF2=	M2\xRXNCVkeHUh?=
JVM-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TsOGlEPTB;MU[3MlQ2OSEQvF2=	MXHTRW5ITVJ?
OVCAR-5	Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1m2VGlEPTB;MU[4MlMxQSEQvF2=	MVrTRW5ITVJ?
Calu-3	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\zeWdKSzVyPUG2PE4{OTFizszN	MUfTRW5ITVJ?
CP66-MEL	NGm0NpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrOW3VKSzVyPUG2PE41OTVizszN	MkfFV2FPT0WU
KYSE-150	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIi2NmdKSzVyPUG2PU43OzZizszN	NWP6Z\|U4W0GQR1XS
Daoy	M2e1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXYTWM2OD1zNkmuPFkyKM7:TR?=	M2rXdXNCVkeHUh?=
HUTU-80	NVriV5JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4ntNmlEPTB;MUexMlA{OiEQvF2=	MXTTRW5ITVJ?
SW620	M4[zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknWTWM2OD1zN{GuOVM2KM7:TR?=	NXzDWZlsW0GQR1XS
HuO-3N1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfJTWM2OD1zN{KuNlc{KM7:TR?=	MWnTRW5ITVJ?
HH	NYXlPJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33sT2lEPTB;MUezMlg1QCEQvF2=	NUTVUnJ3W0GQR1XS
ME-180	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEj6epFKSzVyPUG3OE4xOTZizszN	NX7XOIRGW0GQR1XS
SW756	NXzXe49ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrTO4ZKSzVyPUG3OE45PjNizszN	MYHTRW5ITVJ?
LNCaP-Clone-FGC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;x[2lEPTB;MUe1Mlg3OSEQvF2=	NV;kS4l6W0GQR1XS
YT	NFLERlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jXSWlEPTB;MUe2MlM6QSEQvF2=	M1r3TnNCVkeHUh?=
EW-3	NH;FTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTF5Nj61OVUh\|ryP	NIDjWm9USU6JRWK=
COLO-741	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPOPHFKSzVyPUG3O{42PjFizszN	NIrKUZhUSU6JRWK=
SK-NEP-1	M1vacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTF5Nz64NFYh\|ryP	MlvxV2FPT0WU
NB10	NYnXb3pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[zN\|BuUUN3ME2xO\|cvQDR4IN88US=>	M4nJOnNCVkeHUh?=
SF126	NYDQZ5NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI[4dlZKSzVyPUG3PU41OzJizszN	NYnDfYpTW0GQR1XS
NCI-H522	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfUZ4NKSzVyPUG4NU4xPTlizszN	MWPTRW5ITVJ?
PSN1	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjyTWM2OD1zOEGuOlYh\|ryP	M3zhc3NCVkeHUh?=
GI-ME-N	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;zRmlEPTB;MUixMlY4OiEQvF2=	NETVe5JUSU6JRWK=
SBC-5	Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\ZWnc5UUN3ME2xPFEvQTN2IN88US=>	NIHhRnhUSU6JRWK=
ONS-76	M3rMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL6TWM2OD1zOEKuN\|g4KM7:TR?=	MV\TRW5ITVJ?
LOUCY	NFGxUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf3Z\|BXUUN3ME2xPFIvPjh6IN88US=>	MX;TRW5ITVJ?
SN12C	NYnoc2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3FVVVKSzVyPUG4Nk45OjlizszN	M2\EVHNCVkeHUh?=
A427	Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTF6ND62N\|Eh\|ryP	M3TjNHNCVkeHUh?=
DOK	NVHZeHpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrS[3BKSzVyPUG4OE43PDNizszN	MWnTRW5ITVJ?
MDA-MB-415	NUTDe4pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXRboNKSzVyPUG4OE43PTFizszN	NF32OHJUSU6JRWK=
MRK-nu-1	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonYTWM2OD1zOESuPVczKM7:TR?=	MmHIV2FPT0WU
LB2241-RCC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NET2ZnFKSzVyPUG4OU4yPDVizszN	NV7ZUZJmW0GQR1XS
NCI-H1563	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jhXGlEPTB;MUi1MlIxQSEQvF2=	MkHtV2FPT0WU
MDA-MB-453	M4XsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LZbGlEPTB;MUi2Mlk1OSEQvF2=	M{exc3NCVkeHUh?=
MONO-MAC-6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;VWGVyUUN3ME2xPFcvOzl{IN88US=>	NV\1WldHW0GQR1XS
CAPAN-1	NWHYTXhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTF6Nz60OVMh\|ryP	M{HTbnNCVkeHUh?=
SK-LU-1	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLMTWM2OD1zOEiuOFI5KM7:TR?=	MlT6V2FPT0WU
NCI-H1299	M4rPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjKTWM2OD1zOEiuO\|E6KM7:TR?=	MnG2V2FPT0WU
KG-1	NIe5O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfGdFVKSzVyPUG4PU44QThizszN	M{DtW3NCVkeHUh?=
ETK-1	NVHx[GN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LRZWlEPTB;MUmwMlE5OSEQvF2=	MVrTRW5ITVJ?
NCI-H838	M4HhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrMOYE4UUN3ME2xPVAvOzRizszN	NXPHdml5W0GQR1XS
HCE-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTF7MD65PVIh\|ryP	MlXNV2FPT0WU
A2780	NYLTSFNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPYTWM2OD1zOUKuPFkyKM7:TR?=	NGDucItUSU6JRWK=
COLO-668	M1X2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHWzblBKSzVyPUG5N{4yPTdizszN	MUHTRW5ITVJ?
HGC-27	NWHDZo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTF7NT61N\|gh\|ryP	M2fKcnNCVkeHUh?=
SW1088	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTF7NT62O\|ch\|ryP	NEjDfXdUSU6JRWK=
KOSC-2	M1\XTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moi0TWM2OD1zOUWuPFE5KM7:TR?=	M3fjOnNCVkeHUh?=
TE-1	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\HcJJ3UUN3ME2xPVYvOjZizszN	NYThUGtFW0GQR1XS
SW780	MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TtdmlEPTB;MUm2Mlc{PCEQvF2=	NIC2XWRUSU6JRWK=
22RV1	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jlV2lEPTB;MUm3MlQzPCEQvF2=	MlvqV2FPT0WU
IA-LM	NEXITndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7ZTWM2OD1zOUeuPFIzKM7:TR?=	M2G1T3NCVkeHUh?=
TE-5	NGfMRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXLNJNKSzVyPUG5PE4xOzNizszN	NIXJO3VUSU6JRWK=
JVM-3	NHXNdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17SZmlEPTB;MUm4MlQyQSEQvF2=	M4O0S3NCVkeHUh?=
HT55	M{jPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLPWWcxUUN3ME2xPVkvOTl{IN88US=>	MYfTRW5ITVJ?
QIMR-WIL	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C1N2lEPTB;MkCwMlEyPiEQvF2=	NEnocJBUSU6JRWK=
SJRH30	NXjPWYhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHnTWM2OD1{MECuOVE2KM7:TR?=	MlrWV2FPT0WU
COLO-679	NHPNPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTJyMD64OVkh\|ryP	MYjTRW5ITVJ?
MDA-MB-231	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{G2PGlEPTB;MkCwMlkxOiEQvF2=	MXXTRW5ITVJ?
MFM-223	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorPTWM2OD1{MEGuOVg4KM7:TR?=	MX;TRW5ITVJ?
MFE-280	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nCUmlEPTB;MkCxMlk3OSEQvF2=	Mk\xV2FPT0WU
LAMA-84	NUPJ[Y56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjXTW1VUUN3ME2yNFIvODd\|IN88US=>	NXn2b4xVW0GQR1XS
LS-1034	NWXnR2dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTJyMj61OVMh\|ryP	MlPyV2FPT0WU
NCI-H345	NFHnb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrRNlBKSzVyPUKwN{4xOjdizszN	NI\oRYtUSU6JRWK=
KYSE-70	M3XTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTJyMz64O\|kh\|ryP	M2W2T3NCVkeHUh?=
EGI-1	NVrPTm9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nGT2lEPTB;MkC0Mlg{OyEQvF2=	NVnyT4poW0GQR1XS
RPMI-2650	M4TRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYK4NGtwUUN3ME2yNFUvPDZ5IN88US=>	NI\CS45USU6JRWK=
NCI-H1651	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml61TWM2OD1{ME[uO\|Mh\|ryP	NUC0SWs{W0GQR1XS
HPAF-II	NVL5eYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWi0TIRWUUN3ME2yNFkvPjdzIN88US=>	M4jUSHNCVkeHUh?=
NUGC-3	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TTVWlEPTB;MkC5MlY4QCEQvF2=	MkLaV2FPT0WU
DJM-1	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTyTWM2OD1{MEmuPFk4KM7:TR?=	NIS3PZBUSU6JRWK=
MHH-PREB-1	M2XMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\JTWM2OD1{MUCuN\|gyKM7:TR?=	MoHuV2FPT0WU
EW-18	NVPVT4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvITWM2OD1{MUCuO\|Y{KM7:TR?=	NEL4NGxUSU6JRWK=
BT-20	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfneoVKSzVyPUKxNE46QDZizszN	NXS3XlZSW0GQR1XS
A431	NV[y[VJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TMSWlEPTB;MkGxMlI6QSEQvF2=	NXLYfXBQW0GQR1XS
TCCSUP	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDsboNoUUN3ME2yNVEvPTN\|IN88US=>	NV\RfWNMW0GQR1XS
HO-1-N-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFv4XXVKSzVyPUKxNk45QTRizszN	MnXnV2FPT0WU
NCI-H69	NWDtfXE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFP5OJFKSzVyPUKxOE4yQDVizszN	MYfTRW5ITVJ?
ES7	NGrSemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7NTWM2OD1{MUSuPFc5KM7:TR?=	M3LRSXNCVkeHUh?=
C3A	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJzNT61O\|Uh\|ryP	MULTRW5ITVJ?
UACC-257	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTJzNz60N{DPxE1?	NVXQV4hmW0GQR1XS
DMS-153	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTtTWM2OD1{MUeuPFM3KM7:TR?=	Moj5V2FPT0WU
LB771-HNC	M2rRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mme3TWM2OD1{MUeuPFk{KM7:TR?=	MUXTRW5ITVJ?
HOS	M3mxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJzOD65JO69VQ>?	MULTRW5ITVJ?
THP-1	M4TjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\2cVZKSzVyPUKxPU43ODZizszN	MXrTRW5ITVJ?
SCC-4	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHUPZdKSzVyPUKyNE4{PTNizszN	M1;oR3NCVkeHUh?=
SCC-3	MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1z6PWlEPTB;MkKwMlU4PyEQvF2=	NWr0ZmY4W0GQR1XS
BC-1	M1e3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzXcnVKSzVyPUKyNE44QTlizszN	MX3TRW5ITVJ?
NCI-H1618	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1H4ZWlEPTB;MkKxMlAyQCEQvF2=	NH:yVGxUSU6JRWK=
CaR-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTtS5NuUUN3ME2yNlEvOjVzIN88US=>	M3i4[nNCVkeHUh?=
NCI-H1355	NU[1doIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\yWGlEPTB;MkKxMlM4PyEQvF2=	NUOzXo5mW0GQR1XS
NCI-H1993	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\kTWM2OD1{MkKuNlM6KM7:TR?=	NUjaRW9GW0GQR1XS
NCI-H1623	NHnTT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjSSm1ZUUN3ME2yNlIvOzh7IN88US=>	NX[wbZhLW0GQR1XS
AGS	NYrrZlFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJ{Mj61NlMh\|ryP	NVr0WpFrW0GQR1XS
SAS	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrlTWM2OD1{MkOuO\|k3KM7:TR?=	MmnVV2FPT0WU
HCC1937	MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIS2bVZKSzVyPUKyOE4{QDlizszN	NWnEfolvW0GQR1XS
NCI-H209	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3Td3FKSzVyPUKyOk42OyEQvF2=	NFLaZZdUSU6JRWK=
NCI-H322M	NXzUOpJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPu[mZKSzVyPUKyPE4xOTlizszN	NGToN\|lUSU6JRWK=
CHL-1	NEXFSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrNZ3FWUUN3ME2yNlgvOTNizszN	MomzV2FPT0WU
NCI-H630	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHf1OI5KSzVyPUKzNk45QTdizszN	NUi1W\|MzW0GQR1XS
5637	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7JVGlKSzVyPUKzN{4xODNizszN	M1HIfHNCVkeHUh?=
MSTO-211H	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TreGlEPTB;MkOzMlI4PiEQvF2=	NGnBW5VUSU6JRWK=
YAPC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TnVGlEPTB;MkO0MlI2OyEQvF2=	MkfJV2FPT0WU
SW1783	M4rPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TuW2lEPTB;MkO0MlQyKM7:TR?=	M{\USHNCVkeHUh?=
GB-1	MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJ\|NT6xO\|ch\|ryP	NVfWOFdrW0GQR1XS
NCI-H520	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYi2dmRsUUN3ME2yN\|UvPzRzIN88US=>	NFPhTlNUSU6JRWK=
NOMO-1	M4rxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXGU2VKSzVyPUKzOk4xOiEQvF2=	NYLH[pRsW0GQR1XS
NCCIT	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXEbWg3UUN3ME2yN\|YvQDd\|IN88US=>	Mn;3V2FPT0WU
SW954	NWHWNIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHob\|RlUUN3ME2yN\|cvQDZ6IN88US=>	MXHTRW5ITVJ?
MOLT-4	M{nuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\CcJdKSzVyPUK0NU4zODlizszN	NFfnbpZUSU6JRWK=
EB2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLQTWM2OD1{NEGuPVA4KM7:TR?=	NEfYSI1USU6JRWK=
IPC-298	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnDU\|NKSzVyPUK0Nk4xPzJizszN	M{LXTHNCVkeHUh?=
GP5d	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJ2Mj62NVYh\|ryP	MlLlV2FPT0WU
HN	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnDNHhKUUN3ME2yOFIvQTlzIN88US=>	Mn3sV2FPT0WU
BFTC-909	M{j6N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\aVGlEPTB;MkSzMlEyQCEQvF2=	M1zLNnNCVkeHUh?=
ES5	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHNOW1KSzVyPUK0OU4xOzhizszN	MXnTRW5ITVJ?
SK-HEP-1	NELOb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPQTWM2OD1{NE[uNFQ{KM7:TR?=	NX\oWnFYW0GQR1XS
T47D	M1rCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n5NWlEPTB;MkS3MlAyOyEQvF2=	NGC4XpNUSU6JRWK=
KYSE-510	NGjUR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjZTWM2OD1{NEeuOVE4KM7:TR?=	M1PWWHNCVkeHUh?=
LC-1F	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;ZSWlEPTB;MkS4MlE2PiEQvF2=	NHXzenVUSU6JRWK=
NCI-H1693	MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHVNFBvUUN3ME2yOFkvPDl3IN88US=>	NGnU[3pUSU6JRWK=
COR-L23	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmm1TWM2OD1{NUCuOFEzKM7:TR?=	NVn4folKW0GQR1XS
NCI-H2228	M4XLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnn4TWM2OD1{NUCuPFY1KM7:TR?=	M4\yV3NCVkeHUh?=
NCI-H460	M3jpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;uSGlEPTB;MkWxMlQyPyEQvF2=	M323WXNCVkeHUh?=
TGBC1TKB	NVjT[GxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7zTIhqUUN3ME2yOVIvQDd3IN88US=>	MXHTRW5ITVJ?
NCI-H1304	NVXIV\|c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LZcWlEPTB;MkWzMlE2PiEQvF2=	MmSzV2FPT0WU
CAL-27	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXvOId1UUN3ME2yOVMvPDh3IN88US=>	NVzHS2diW0GQR1XS
NCI-H187	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj6eIRKSzVyPUK1Ok44PiEQvF2=	Ml:5V2FPT0WU
HSC-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPFWIdKSzVyPUK1PE42QDRizszN	NIL5PGVUSU6JRWK=
CAL-39	M4\5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYi0OXM{UUN3ME2yOlAvOjd{IN88US=>	MlPNV2FPT0WU
HuH-7	NHLPOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDmNHFnUUN3ME2yOlAvQTl4IN88US=>	MnfFV2FPT0WU
MMAC-SF	NYDPZZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HSTWlEPTB;Mk[xMlE6OiEQvF2=	NYK4fIJMW0GQR1XS
VA-ES-BJ	NUK0R5pJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rlRWlEPTB;Mk[xMlkyQCEQvF2=	NEPITW1USU6JRWK=
A673	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\ZRlNNUUN3ME2yOlcvODJ3IN88US=>	NX\reHNyW0GQR1XS
LU-165	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\BNGtYUUN3ME2yOlcvQTRzIN88US=>	M1XsUHNCVkeHUh?=
CAL-12T	M1zZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2H0[2lEPTB;Mk[4MlM3PiEQvF2=	M1XyNXNCVkeHUh?=
RD	NYLTdlZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXu0XGF7UUN3ME2yOlkvOTF7IN88US=>	MYfTRW5ITVJ?
MDA-MB-468	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fvS2lEPTB;Mk[5MlM{OyEQvF2=	NYrlNWhwW0GQR1XS
LN-405	MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPBPZdKSzVyPUK2PU44ODhizszN	MYTTRW5ITVJ?
MHH-CALL-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPwRllDUUN3ME2yOlkvQTJizszN	MUnTRW5ITVJ?
ES3	NIDGeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXMS2V[UUN3ME2yO\|AvOzV6IN88US=>	MmHkV2FPT0WU
SK-MEL-3	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmG2TWM2OD1{N{WuOFU4KM7:TR?=	M3LCWHNCVkeHUh?=
TE-10	NX3G[I9UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mle3TWM2OD1{N{[uOFM6KM7:TR?=	NE\C[5JUSU6JRWK=
BEN	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zXNGlEPTB;Mke2MlQ3OSEQvF2=	M1PH[3NCVkeHUh?=
NB69	NFLiU\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJ5Nz60NFUh\|ryP	M1HienNCVkeHUh?=
CAMA-1	NF;Xe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nSS2lEPTB;Mke4MlI4QSEQvF2=	MXnTRW5ITVJ?
NCI-H1792	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TCUmlEPTB;Mke5MlE5PyEQvF2=	MmjLV2FPT0WU
UACC-893	NWDNXo9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTJ6MD61OEDPxE1?	NI\VNFFUSU6JRWK=
TGW	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LVNmlEPTB;MkizMlA2QCEQvF2=	NHjOOJZUSU6JRWK=
SH-4	NEjsU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJ6Mz6xNlMh\|ryP	MWHTRW5ITVJ?
NCI-H2009	NIjhN\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DJWmlEPTB;MkizMlk2OyEQvF2=	M{HqSXNCVkeHUh?=
T84	M4S5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJ6ND62OlUh\|ryP	NF\5T2xUSU6JRWK=
EW-7	NEO0SJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvybJlKSzVyPUK4OU4zOzJizszN	NUXXN4JjW0GQR1XS
NCI-H1882	NWHkTHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDNO3NKSzVyPUK4Ok4xOzVizszN	Ml\nV2FPT0WU
GMS-10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ6Nz6xPFMh\|ryP	M3f6cHNCVkeHUh?=
HC-1	NWPKfHRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjtVpJKSzVyPUK5NE43ODJizszN	M4nySnNCVkeHUh?=
ABC-1	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1G2WWlEPTB;MkmxMlA3QSEQvF2=	NHy4RXVUSU6JRWK=
HuP-T3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTJ7Mj6xOFYh\|ryP	NHfVT29USU6JRWK=
HT-1197	NEX6S4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTMeI1FUUN3ME2yPVIvQDd7IN88US=>	NGnte3BUSU6JRWK=
SHP-77	NEm5d\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nGSGlEPTB;Mkm1MlU6PyEQvF2=	NEXBfGdUSU6JRWK=
NCI-H524	M4DSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJ7NT63Olkh\|ryP	MW\TRW5ITVJ?
SW626	MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTJ7Nj6xNVUh\|ryP	NGjvVFVUSU6JRWK=
NCI-H2347	M2[zbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJ7Nj60NlUh\|ryP	NVPLe\|ZDW0GQR1XS
U251	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHhcFFwUUN3ME2yPVgvPDN6IN88US=>	MWrTRW5ITVJ?
RL95-2	NIKw[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\GXGlEPTB;M{CwMlI1PyEQvF2=	NGTucHVUSU6JRWK=
C2BBe1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2f3TWlEPTB;M{CwMlY6OSEQvF2=	NVXUPZU6W0GQR1XS
HLE	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEO5ZpVKSzVyPUOwNU45OThizszN	NHvGTpVUSU6JRWK=
COLO-680N	M{PEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnETWM2OD1\|MEKuPFk{KM7:TR?=	NV\MSoxUW0GQR1XS
PLC-PRF-5	NWXuXoNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\SR21KSzVyPUOwOE46ODdizszN	MkjDV2FPT0WU
SCC-15	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\2TWM2OD1\|ME[uNFE4KM7:TR?=	M17oV3NCVkeHUh?=
ECC12	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4P2fWlEPTB;M{GwMlI2PCEQvF2=	NH3ETVFUSU6JRWK=
A388	NYLvfVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrIeJRKSzVyPUOxNk4xOjJizszN	NGPYPVJUSU6JRWK=
ES1	NX7UTWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LDZmlEPTB;M{GyMlE5QSEQvF2=	MWjTRW5ITVJ?
J-RT3-T3-5	NHezb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzFTWM2OD1\|MUOuOVIyKM7:TR?=	M4\VW3NCVkeHUh?=
SNU-475	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTNzND6wPVEh\|ryP	NIfR[XJUSU6JRWK=
647-V	NEG2R3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXGTWM2OD1\|MUSuOlc{KM7:TR?=	MWHTRW5ITVJ?
IMR-5	NV7iT5QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWm2U4xFUUN3ME2zNVUvOzhizszN	MlLsV2FPT0WU
EW-24	NYjFc3pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXkXI1KSzVyPUOyNE4xPyEQvF2=	NEjodYxUSU6JRWK=
CAL-51	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[0NmlEPTB;M{KxMlQxOyEQvF2=	MoLCV2FPT0WU
HD-MY-Z	M1f2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTN{MT60NFkh\|ryP	M4LM[3NCVkeHUh?=
EW-13	NHmwcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG2V\|Z4UUN3ME2zNlIvPDJ2IN88US=>	M2PBWHNCVkeHUh?=
SK-N-FI	M3PzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXZZVF[UUN3ME2zNlIvPDV{IN88US=>	NX;LOnA{W0GQR1XS
BHY	NWLmS3pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX1TWM2OD1\|MkOuNVc2KM7:TR?=	NETv[WpUSU6JRWK=
OCUB-M	M1rK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTN{Mz60N\|Qh\|ryP	NF2xSHNUSU6JRWK=
HCC1954	M{DyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInsUmpKSzVyPUOyN{42QDJizszN	M2HQT3NCVkeHUh?=
SK-MEL-24	M1iydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnv0TWM2OD1\|MkSuNVEyKM7:TR?=	NVzQSFV[W0GQR1XS
NTERA-S-cl-D1	NXH4[nlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUK5TYVGUUN3ME2zNlYvPDh7IN88US=>	NU\kWpBoW0GQR1XS
SK-MEL-30	NVGzNnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnfVTWM2OD1\|Mk[uO\|M5KM7:TR?=	NGPDdYFUSU6JRWK=
LS-123	NXnJZ\|BxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXlOmpKSzVyPUOyPE4yPjRizszN	NWjxRoFRW0GQR1XS
SF268	MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\rS3ZHUUN3ME2zN\|AvOjZ3IN88US=>	M4fMdHNCVkeHUh?=
BT-474	NHjhVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjGbpNKSzVyPUOzNk41OThizszN	NHv5WFBUSU6JRWK=
NCI-H1522	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\WU2lEPTB;M{O0MlM{QSEQvF2=	NW\yOFY2W0GQR1XS
LC-2-ad	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrqVFRrUUN3ME2zN\|YvPTlzIN88US=>	NX3kd\|RJW0GQR1XS
LAN-6	NFS4d\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\KdYZyUUN3ME2zN\|YvQTd5IN88US=>	NHvTR3dUSU6JRWK=
ARH-77	NY\FVnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTN\|Nz6zNkDPxE1?	Mm\mV2FPT0WU
HuO9	NYT2UHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnkcVhKSzVyPUOzO{41PyEQvF2=	MXzTRW5ITVJ?
MLMA	M1S5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHvTWM2OD1\|M{iuNVU2KM7:TR?=	MlXtV2FPT0WU
Raji	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVKwSYx4UUN3ME2zN\|gvOzhizszN	MVjTRW5ITVJ?
GT3TKB	NXPSVpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTN\|OD60NVIh\|ryP	MVXTRW5ITVJ?
NCI-H441	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH:0OZNKSzVyPUO0NU41OThizszN	NX23fJU6W0GQR1XS
NCI-H2030	NFLNWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPodJZKSzVyPUO0NU43ODlizszN	NVHLNGx[W0GQR1XS
VM-CUB-1	NXjDUpVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjtNmlKSzVyPUO0Nk43OzZizszN	MkjDV2FPT0WU
KP-4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HGbGlEPTB;M{SzMlc{OyEQvF2=	NXu5OmM1W0GQR1XS
PF-382	M{D0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX65O2NTUUN3ME2zOFQvPDJ{IN88US=>	NYjvW4F[W0GQR1XS
NB13	MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PIOGlEPTB;M{S1MlU5KM7:TR?=	NV3MbG1GW0GQR1XS
D-502MG	M3XGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzRZm5mUUN3ME2zOFUvQDF{IN88US=>	NILmfJVUSU6JRWK=
CAL-54	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\iPFM4UUN3ME2zOFUvQDd7IN88US=>	M3jQfHNCVkeHUh?=
DOHH-2	NWno[3VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTN2Nj62OUDPxE1?	M{DGVHNCVkeHUh?=
SK-PN-DW	M2\jTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfG[IZTUUN3ME2zOFcvPDJ4IN88US=>	MnzJV2FPT0WU
NCI-H720	NVTDZphKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXJTWM2OD1\|NEmuPFQ3KM7:TR?=	MVjTRW5ITVJ?
SW1990	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvyTWM2OD1\|NUGuNlgh\|ryP	NF7tWWtUSU6JRWK=
NCI-H2196	NIHENm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN3Mj62NlQh\|ryP	M3zyR3NCVkeHUh?=
P30-OHK	M{T3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HxcWlEPTB;M{WzMlA3OyEQvF2=	MVPTRW5ITVJ?
NCI-H358	NYT6WI9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfVTWM2OD1\|NUWuN\|U3KM7:TR?=	M1HGcXNCVkeHUh?=
CW-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTN3Nj61Nlkh\|ryP	NYrqVHB4W0GQR1XS
COLO-678	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\ZU2VJUUN3ME2zOVcvQDZ\|IN88US=>	NI\wWVRUSU6JRWK=
NCI-H2126	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;STWlEPTB;M{W4MlUzOSEQvF2=	NFf1VYNUSU6JRWK=
DMS-53	M1fpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HlUGlEPTB;M{W4MlcyOSEQvF2=	MVPTRW5ITVJ?
NCI-H1838	M3z4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7wSlBKSzVyPUO1PU46QDdizszN	NGqzOI9USU6JRWK=
SJSA-1	M33DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nCVGlEPTB;M{[wMlk{QSEQvF2=	NWD1W5hyW0GQR1XS
ChaGo-K-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrvTWM2OD1\|NkOuPVI1KM7:TR?=	M1G2c3NCVkeHUh?=
IST-SL2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz4TWM2OD1\|N{KuPVI3KM7:TR?=	MUPTRW5ITVJ?
U-266	NVKxb5ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7zRZJKSzVyPUO3N{4yOzJizszN	NXnwV2o3W0GQR1XS
P31-FUJ	NFW3cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTN5Nj65OlQh\|ryP	M2nqfHNCVkeHUh?=
HCC2157	NE\hb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[1XHBkUUN3ME2zO\|gvOTZzIN88US=>	NEPkN\|FUSU6JRWK=
COR-L88	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLFTWM2OD1\|OEOuOlc4KM7:TR?=	NIPCbYNUSU6JRWK=
NCI-H596	NInsUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULG[Zp[UUN3ME2zPFUvOzRizszN	M4TSOXNCVkeHUh?=
GOTO	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Xib2lEPTB;M{mwMlY1OSEQvF2=	MnHiV2FPT0WU
NCI-H719	M1fRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTN7MT64PVMh\|ryP	Mn7xV2FPT0WU
MN-60	MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTN7Mz65OFgh\|ryP	Ml3EV2FPT0WU
IST-SL1	MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHi3W2RKSzVyPUO5OE41ODZizszN	MlvUV2FPT0WU
TE-6	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P2cmlEPTB;M{m3MlI2PCEQvF2=	MmDVV2FPT0WU
SW962	NXnYNYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrwTWM2OD1\|OUiuOlkh\|ryP	MUHTRW5ITVJ?
FADU	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1e2[2lEPTB;NECzMlA5OyEQvF2=	MUnTRW5ITVJ?
ECC4	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTRyOD60OVgh\|ryP	NWPNOHNoW0GQR1XS
MES-SA	NGPmO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIezN5ZKSzVyPUSwPU46QCEQvF2=	NHzGeYFUSU6JRWK=
NCI-H716	NE\KeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rhVGlEPTB;NEGwMlA4PSEQvF2=	M3;B[XNCVkeHUh?=
GR-ST	NUnlZ5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHFTWM2OD12MUCuOFk4KM7:TR?=	MWLTRW5ITVJ?
KY821	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPnbXlKSzVyPUSxOE4xQDZizszN	MmHpV2FPT0WU
NCI-H2141	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEmxT3RKSzVyPUSyOE4{QDhizszN	NEHTNGhUSU6JRWK=
MDA-MB-134-VI	NHm1PW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvYTWM2OD12M{GuNFM{KM7:TR?=	M3iwRXNCVkeHUh?=
RH-1	NYjyW3N4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXl[G9KSzVyPUSzOU4xQSEQvF2=	NX\FbGU5W0GQR1XS
AM-38	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTR\|OD61OEDPxE1?	NGXxVIFUSU6JRWK=
BL-70	M4fCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTR\|OT60Nlkh\|ryP	NH3hU4ZUSU6JRWK=
COLO-684	NUn3NndYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK4TWM2OD12NEiuPFg5KM7:TR?=	MX7TRW5ITVJ?
DMS-79	NU\sVpVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mni2TWM2OD12NEmuOlgh\|ryP	NVnqNmNMW0GQR1XS
EW-1	M4rhOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEH6[olKSzVyPUS1Nk45QDhizszN	Mor6V2FPT0WU
MS-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mme3TWM2OD12NUSuN\|g2KM7:TR?=	MWTTRW5ITVJ?
A4-Fuk	M{TQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXuzUJNWUUN3ME20OVQvPTB5IN88US=>	NU\yN2pHW0GQR1XS
TALL-1	NGPyZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX75NpIzUUN3ME20OVUvOjl5IN88US=>	MYjTRW5ITVJ?
SCLC-21H	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTR3NT62PVkh\|ryP	M2fIe3NCVkeHUh?=
KMS-12-PE	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR3Nj64NlIh\|ryP	NF[5VHVUSU6JRWK=
TE-441-T	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\HTWM2OD12NUeuNVg3KM7:TR?=	M4jGdHNCVkeHUh?=
A3-KAW	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLmc5dKSzVyPUS2NE45PDFizszN	M4q2dnNCVkeHUh?=
NCI-H1092	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTR4Mz65OFMh\|ryP	M{PzXHNCVkeHUh?=
COR-L279	NGO1OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[yW3VKSzVyPUS2OE45PDdizszN	MXHTRW5ITVJ?
NCI-SNU-5	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLyTWM2OD12N{KuNlgh\|ryP	MmHoV2FPT0WU
JAR	NHizW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHr5fIxKSzVyPUS3OE44QDhizszN	NYHHfnV4W0GQR1XS
NCI-H446	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NETr[oJKSzVyPUS3O{4xQCEQvF2=	MkO0V2FPT0WU
HDLM-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWX1R4liUUN3ME20PFAvQDZ7IN88US=>	MV7TRW5ITVJ?
D-283MED	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2roOmlEPTB;NEi4MlkzPCEQvF2=	NGTFfZBUSU6JRWK=
NCI-H1395	NGfGOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3DbJJKSzVyPUS4PU4xODRizszN	Ml\ZV2FPT0WU
RPMI-6666	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTjTWM2OD12OUGuN\|k5KM7:TR?=	MkC3V2FPT0WU
CPC-N	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTVyMj6wOlMh\|ryP	M3nYbHNCVkeHUh?=
EC-GI-10	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGySG9KSzVyPUWwNk4yPjlizszN	MoPZV2FPT0WU
CA46	NU\sWFNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPh[2xKSzVyPUWwOE41ODdizszN	NYXSUphJW0GQR1XS
EHEB	NUPmPZdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTVyNz6yNFgh\|ryP	M{fzXHNCVkeHUh?=
RPMI-8402	NFfGS\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;XeWlEPTB;NUGwMlAzOSEQvF2=	NUfSPXJPW0GQR1XS
DU-4475	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rXN2lEPTB;NUGxMlExOSEQvF2=	MmroV2FPT0WU
P12-ICHIKAWA	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELM[o9KSzVyPUWxNU41OTZizszN	NGr1TlZUSU6JRWK=
NCI-H1694	NVPzN241T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnzTWpQUUN3ME21NVIvPDN7IN88US=>	MVvTRW5ITVJ?
NCI-H2171	NGmzPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojETWM2OD13MUKuO\|A2KM7:TR?=	MYjTRW5ITVJ?
Mo-T	NWLqRYt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HLRWlEPTB;NUG1MlEyPiEQvF2=	NXrNdnV{W0GQR1XS
HL-60	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DrfWlEPTB;NUKyMlkzPCEQvF2=	MYPTRW5ITVJ?
NCI-H1436	NIPKXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTV{Mz6wOlQh\|ryP	NFjwZ5NUSU6JRWK=
NCI-H510A	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLhbHVKSzVyPUWyOE43QTZizszN	Ml3xV2FPT0WU
NCI-H2081	M2LkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITqempKSzVyPUWyOU42OTNizszN	MlS0V2FPT0WU
NB5	NV7mfIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDZeIFOUUN3ME21NlYvPDNizszN	NIDz[5BUSU6JRWK=
NCI-H2227	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj0TIlKSzVyPUWzNE4zPTRizszN	NHLmPJVUSU6JRWK=
HSC-4	M4rFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTV\|OT6yPVMh\|ryP	NUXKV4s{W0GQR1XS
RL	NFjTUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HuemlEPTB;NUSyMlQ1OiEQvF2=	MVXTRW5ITVJ?
EVSA-T	NIK4dpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTV2Mz62PFQh\|ryP	NXzSVZpmW0GQR1XS
NCI-H889	M4faTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zk[GlEPTB;NUS3MlI{KM7:TR?=	NUjxT5R5W0GQR1XS
COLO-320-HSR	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFu0dlZKSzVyPUW1NU4{PSEQvF2=	NFu0fJVUSU6JRWK=
EW-11	M1HLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X3PWlEPTB;NUWyMlM6QSEQvF2=	NUXQb4RbW0GQR1XS
UACC-812	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXm4flJ6UUN3ME21OVkvOzlzIN88US=>	MmPxV2FPT0WU
CAL-148	MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTV4NT6wPFkh\|ryP	NUfoVXl[W0GQR1XS
K052	Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjCTWM2OD13N{muNlE{KM7:TR?=	MWHTRW5ITVJ?
L-428	M2P4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZyMD62O\|Eh\|ryP	M3fWcHNCVkeHUh?=
LP-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnVZ3JKSzVyPU[wN{42QDdizszN	MVfTRW5ITVJ?
ML-2	NHfVXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MleyTWM2OD14ME[uOVc6KM7:TR?=	M1uzTnNCVkeHUh?=
KARPAS-45	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M16w[WlEPTB;NkG4MlIzOSEQvF2=	MWjTRW5ITVJ?
HT	NXXTXFVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUG5VIxSUUN3ME22NlIvPzh3IN88US=>	Mlu4V2FPT0WU
NCI-H226	NIPnVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkO3TWM2OD14MkiuN\|U{KM7:TR?=	M{\oU3NCVkeHUh?=
L-363	NYDV[G1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD0ZopIUUN3ME22OFgvODZ2IN88US=>	M3vlPHNCVkeHUh?=
IM-9	NGWyRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXzblBHUUN3ME22OVEvPTRzIN88US=>	Mn3yV2FPT0WU
TUR	Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTZ5MT6zNlIh\|ryP	NXrDOWJqW0GQR1XS
NCI-SNU-16	NEO5NG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTZ6MD60OlIh\|ryP	NETQXpRUSU6JRWK=
NCI-SNU-1	M1vVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvJc\|hbUUN3ME22PVAvOTd{IN88US=>	NFL2TXlUSU6JRWK=
U-87-MG	M3TrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Lo[mlEPTB;Nkm0MlU5PSEQvF2=	M3PFNnNCVkeHUh?=
KM-H2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLYc2JmUUN3ME22PVkvODV7IN88US=>	MYnTRW5ITVJ?
DEL	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjjUIxKSzVyPUewNE45OzhizszN	MUfTRW5ITVJ?
KARPAS-422	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnoc\|BRUUN3ME23PFkvOzF3IN88US=>	MX3TRW5ITVJ?
BC-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPuU21KSzVyPUiwOU4zODNizszN	M4nIPXNCVkeHUh?=
NCI-H1155	NGfP[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;EOWdyUUN3ME24NVgvODV7IN88US=>	Mk\UV2FPT0WU
NCI-H1581	NYrPUG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjlUohwUUN3ME25NFAvOjNzIN88US=>	MX;TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / CD31 / VE-Cadherin / α-SMA / vimentin; PubMed: 30709379 J Exp Clin Cancer Res NCI-H460 cells were co-cultured with HUVECs in a 3D culture system, and then treated with 1 μM CHIR-99021, 10 μM or 20 μM Cisplatin, or a combination of both, for 24 h. Cells were harvested and immunoblotted with anti-cleaved PARP, anti-CD31, anti-VE-cadherin, anti-α-SMA, anti-vimentin, and anti-β-actin antibodies. CTNNB1; PubMed: 23993102 Cell Treatment with the GSK3β inhibitor CHIR-99021 led to increased levels of β-catenin in RKO and HT29 (non-mutant) cells. β-catenin; PubMed: 24165128 J Biol Chem HeLa cells were treated with 5 μm CHIR-99021 for the indicated times. The samples were analyzed by Western blot.	30709379 23993102 24165128
Growth inhibition assay	Cell viability; PubMed: 22039301 J Immunol HMC-1.2 cells were cultured in the absence or presence of GSK3β inhibitor (CHIR 99021, 3–30 µM) and viability cell count was assessed by trypan blue dye exclusion after 24 h, 48 h or 72 h. All data are presented as the mean ± SEM of three independent experiments conducted in triplicate. p < 0.05, p < 0.001* p < 0.0001*** vs vehicle treated control cells.	22039301
Immunofluorescence	SOX10 / EdU; PubMed: 28174705 Cell Mol Gastroenterol Hepatol Incorporation of EdU (white arrowheads) into SOX10+ ENS (enteric nervous system) cells with and without CHIR-99021. Oct3/4; PubMed: 24779365 BMC Res Notes Fluorescence micrographs showing the protein expression of Brachyury/Oct3/4 after a three day differentiation of ES-D3 cells with BIO (0.5 μM), SB-216763 (5 μM), CHIR-99021 (5 μM), or CHIR-98014 (1 μM). Nuclei were counterstained with DAPI (blue). The merge is shown in yellow. Original magnification 400x. Scale bar = 50 μm.	28174705 24779365

In vivo

Oral administration of CHIR-99021 at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. Oral administration of CHIR-99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively, and the higher dose of CHIR-99021 also reduces hyperglycemia before the oral glucose challenge. ^[1] Administration of CHIR-99021 significantly augments hematopoietic repopulation in recipient mice transplanted with mouse or human hematopoietic stem cells (HSCs), suggesting that GSK-3 is a specific modulator of HSC activity. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cell-free kinase assays: Polypropylene 96-well plates are filled with 300 μL/well buffer (50 mM tris HCl, 10 mM MgCl₂, 1 mM EGTA, 1 mM dithiothreitol, 25 mM β-glycerophosphate, 1 mM NaF, 0.01% BSA, pH 7.5) containing 27 nM GSK-3α or 29 nM GSK-3β, and 0.5 μM biotin-CREB peptide substrate. Various concentrations of CHIR-99021 are added in 3.5 μL of DMSO, followed by 50 μL of ATP stock to yield a final concentration of 1 μM ATP in all cell-free assays. After incubation, triplicate 100-μL aliquots are transferred to Combiplate eight plates containing 100 μL/well 50 μM ATP and 20 mM EDTA. After 1 hour, the wells are rinsed five times with PBS, filled with 200 μL of scintillation fluid, sealed, left 30 minutes, and counted in a scintillation counter. All steps are performed at room temperature.
Cell Research: ^[3]	- Collapse Cell lines: INS-1E Concentrations: Dissolved in DMSO, final concentrations ~ 20 μM Incubation Time: 1, or 4 days Method: Cells are maintained for 24 hours in starvation medium (culture medium with only 5 mM glucose, 1% fetal calf serum). Then cells are exposed to various concentrations of CHIR-99021 for 1, or 4 days. Cell number is measured by staining of cellular DNA with CyQuant dye, which becomes fluorescent when bound to DNA. Fluorescence is measured after 30 minutes of incubation using the FLUOstar Optima reader. Cell replication is determined by BrdUrd incorporation. BrdUrd labeling solution is added to the medium for the last 4 hours before the cells are fixed using FixDenat solution and incubated with monoclonal anti-BrdUrd-POD antibodies. After substrate solution is added to each well, the light emission is measured in a microplate luminometer using the Analyst HT detection system. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female db/db mice or male ZDF rats with type 2 diabetes Dosages: ~48 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	93 mg/mL (185.33 mM)
	Water	Insoluble
	Ethanol	'2 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	24mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download CHIR-99021 (CT99021) HCl SDF

Molecular Weight	501.8
Formula	C₂₂H₁₈Cl₂N_8.HCl
CAS No.	1797989-42-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	Cl.CC1=C[NH]C(=N1)C2=CN=C(NCCNC3=NC=C(C=C3)C#N)N=C2C4=CC=C(Cl)C=C4Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I recently purchased CHIR 99021 to inject mice intraperitoneally. The data sheet says using 10% captisol for in vivo use. Is it for IP injection? Or do you have other solutions to suggest to use for in vivo IP injection of CHIR 99021?
Answer:
The formulation of 15% Captisol is for oral gavage, and S2924 CHIR-99021 (CT99021) HCl in it is a suspension. S2924 CHIR-99021 (CT99021) HCl can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 24mg/ml as a clear solution for IP injection.
Question 2:
How about the half-life of this compound? If it is necessary for daily treatment when the compound is used in long-term experiment?
Answer:
Please change the culture medium each day to add the new comound in it if the duration is more than 72h.
Question 3:
What is the difference between S2924 and S1263? Which one is better for differentiation?
Answer:
S1263 is the free base format of Chir-99021, while S2924 is the HCl salt format. They have the same biological activity but are slightly different in solubility.

GSK-3 Signaling Pathway Map

GSK-3 Inhibitors with Unique Features

Selective GSK-3 Inhibitor

TWS119 : GSK-3β-selective, IC50 of 30 nM.
Most Potent GSK-3 Inhibitor

CHIR-98014 : GSK-3α, IC50=0.65 nM; GSK-3β, IC50=0.58 nM.
GSK-3 Inhibitor in Clinical Trial

Tideglusib : Phase II for Alzheimer's disease.
Newest GSK-3 Inhibitor

AZD1080 : Orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with K_i of 6.9 nM and 31 nM, respectively.

Related GSK-3 Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
LY2090314 ^New

LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
TDZD-8 ^New

TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
TWS119

TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology. GSK-3β inhibition triggers autophagy.
SB216763

SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β. SB216763 activates autophagy.
Tideglusib

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.
CHIR-98014

CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.
BIO

BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

Features:The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
AR-A014418

AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and K_i of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.
IM-12

IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.

Choose Your Country or Region

By Signaling Pathways

By product type

CHIR-99021 (CT99021) HCl